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1. Introduction 
 
The attention to metabolic syndrome (MetS) has risen constantly over the 
years. The increasing number of people affected by obesity, cardiovascular 
diseases and/or diabetes is alarming as it is not only a problem of premature 
death but also of disability, illness and economic costs. It is out of question 
that the change of the environment in the last decades, which comes with 
sedentary life style and poor nutrition habits, is blameable for the substantial 
part of this situation. But how significant is the genetic part? Are there really 
genes that are accountable for this development, too? If yes, which ones are 
to blame? 
 
This thesis is focusing on leptin and adiponectin as well as their receptors. 
These two adipocytokines have brought some furore into research as they 
have changed the knowledge about adipose tissue completely. Both have 
been associated with obesity and type II diabetes as well as MetS. 
Researchers have also shown that they play a crucial role in hunger and 
satiety, which might have a substantial effect on obesity, a feature of MetS. 
But what about their influences on insulin resistance, dyslipidemia or 
hypertension?  
 
Returning to the question from above, this thesis is assuming that there are 
genes that have an influence on the development of MetS. Furthermore it 
wants to show if there are substantial causal effects primarily due to 
polymorphisms in the leptin and adiponectin coding genes, their receptor 
coding genes or the genes that encode their signalling pathway. Genome-
wide association studies (GWAS) are the method of choice in finding these 
polymorphisms in the DNA associated with changes in leptin and adiponectin 
efficiency. If researchers are able to find significant results, they might be 
able to understand to which part genetic variance plays a role in 
pathogenesis. This might either lead to new and individual therapies or to the 
conclusion that the incorporation of better health habits is the only way of 
treatment of MetS.  
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However, it remains interesting to find out what these adipocytokines really 
are, how they function in the human body and what effects they have when 
they do and do not function properly. This thesis has tried to consider all 
these aspects. At first the MetS and its features of pathophysiology are 
described, then the adipocytokines and their signalling pathway in the human 
body. The following explanation of genome-wide association studies is an 
essential background to understand and interpret the study results. Those 
have been divided into real GWAS and further studies as there are not many 
of the first ones and the latter have shown promising outcomes. A discussion 
at the end of every subchapter points out the up-to-date knowledge and 
shows the related difficulties. General results are then summarized in the 
conclusion. 
 
Various opinions, numerous definitions of MetS, indefinite cut-off points and 
new detection methods are only a few difficulties that researchers and this 
thesis have to deal with. As already shortly mentioned, those are pointed out 
in the thesis, as they might be crucial when interpreting studies.  
 
It starts with the question: “What is actually the MetS?” 
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2. Metabolic Syndrome 
2.1. Definitions 
 
To understand how leptin and adiponectin can play a role in development of 
MetS it is important to know what MetS actually is. In general it describes a 
“cluster of risk factors for type II diabetes (T2D), cardiovascular disease 
(CVD) and stroke” [HENNEMAN 2010], which are all diseases that are 
associated with the modern, sedentary, `high energy intake` lifestyle.  
 
Although KYLIN has introduced the concept already in 1923, a standardized 
definition of MetS has not yet been formulated. At the moment there are four 
definitions widely used for classification for MetS, formulated by the World 
Health Organization (WHO), the European Group for the Study of Insulin 
Resistance (EGIR), the National Cholesterol Education Program – Third 
Adult Treatment Panel (NCEP ATP III) and the International Diabetes 
Federation (IDF). All four definitions agree upon the core components of the 
MetS: obesity, insulin resistance (IR), dyslipidaemia and hypertension. 
However, they offer different clinical criteria to identify it. Each of them has 
slightly different levels for each factor and they use different combinations of 
components to diagnose the cluster of risk factors. Therefore direct 
comparisons between studies remain to be difficult or impossible. In the 
chapter “Prevalence” this problem is pointed out and explained in detail as it 
also has an effect on the interpretation of study results later on. 
 
The four definitions named above are explained subsequently. They are also 
put into a table with the exact, corresponding components for easier 
comparison of the cut-off points. 
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2.1.1. WHO 
 
The definition of the WHO is based on the assumption that insulin resistance 
is the major contributor to the MetS. Their clinical criteria are: glucose 
intolerance, impaired glucose tolerance (IGT) or diabetes mellitus and/or 
insulin resistance together with two or more of the other components like 
hypertension, elevated plasma triglycerides, central obesity and 
microalbuminuria [WHO 1999; ALBERTI et al. 2006]. Within this definition 
central obesity is measured as waist-to-hip ratio (WHR), which is an index of 
the relative accumulation of abdominal fat. Eye-catching is the fact that WHO 
also uses microalbuminuria as a factor, which is not common within other 
definitions. 
2.1.2. EGIR 
 
The members of the EGIR have criticised the syndrome definition by the 
WHO Expert Committee and proposed an altered definition, which has to be 
used only in non-diabetic cases [BALKAU and CHARLES 1999]. They 
proposed to use fasting insulin sensitivity to estimate insulin resistance and 
impaired fasting glucose (IFG) instead of IGT and also slightly altered cut-
points for hypertension, triglycerides and high-density lipoprotein (HDL) 
cholesterol. For central obesity measurement they recommend to use waist 
circumference (WC) instead of the WHR [ALBERTI et al. 2006]. 
2.1.3. NCEP ATP III 
 
The definition made by NCEP ATP III was developed to facilitate the 
diagnosis of MetS in clinical practice. It differs substantially to the other two 
definitions because it does not include a measurement of insulin resistance 
and it treats glucose abnormalities with equal importance as the other 
components. For them three or more of the five suggested factors (obesity, 
HDL-cholesterol, triglycerides, blood pressure (BP) and fasting plasma 
glucose) have to be present to diagnose MetS [GRUNDY et al. 2004; 
ALBERTI et al. 2006]. 
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2.1.4. IDF 
 
As already mentioned numerous definitions make comparisons between 
individual studies very difficult. Consequently, the IDF decided to create a 
new worldwide definition for MetS as well as to establish new clinical criteria 
that should replace other definitions. The NCEP ATP III definition from 2001 
was used as a fundament and then modified and updated (e.g ethnicity 
specific cut-points for WC). For IDF a person, to be identified as having the 
MetS, must have central obesity (defined as waist circumference ≥ 94 cm for 
Europid men and ≥ 80 cm for Europid women) plus any two of four additional 
factors [ALBERTI et al. 2006]. Despite all attempts it did not replace the other 
definitions but added new criteria instead. Therefore the problem of 
comparability remains. 
 
Factors WHO (1999) EGIR (1999) NCEP ATP III (2004) IDF 
 Glucose intolerance, 
IGT or diabetes and/or 
insulin resistance 
together with two or 
more of the following: 
Insulin resistance Plus 
two of the following: 
Three or more of the 
following five risk 
factors: 
Central obesity plus 
two of four 
additional risk 
factors. 
Fasting plasma 
glucose 
 ≥ 6.1 mmol/l (110 mg/dl) 
but non-diabetic 
≥ 5.6 mmol/l (100 
mg/dl) 
≥ 5.6 mmol/l (100 
mg/dl) or previously 
diagnosed Type 2 
diabetes. 
Blood pressure ≥140/90 mmHg ≥ 140/90 mmHg or 
treatment 
≥ 130/ ≥ 85 mmHg ≥ 130/ ≥ 85 mmHg 
or treatment 
Triglycerides Raised plasma 
triglycerides: ≥ 1.7 
mmol/l (150 mg/dl) 
and/or 
> 2.0 mmol/l (178 mg/dl) 
or treatment and/or 
≥ 1.7 mmol/l (150 
mg/dl) 
≥ 1.7 mmol/l 
(150mg/dl) or 
specific treatment 
HDL- cholesterol Men: < 0.9 mmol/l (35 
mg/dl) 
< 1.0 mmol/l (39 mg/dl) or 
treatment 
Men: < 1.03 mmol/l 
(40 mg/dl) 
Men: < 1.03 mmol/l 
(40 mg/dl) 
 Women: < 1.0 mmol/l 
(39 mg/dl) 
 Women: < 1.29 
mmol/l (50 mg/dl) 
Women: < 1.29 
mmol/l (50 mg/dl) or 
specific treatment 
Obesity Men: WHR > 0.90 
and/or BMI > 30 kg/m2 
Men: WC ≥ 94 cm Men: WC > 102 cm Ethnicity specific 
cut-points of WC 
 Women: WHR > 0.85 
and/or BMI > 30 kg/m2 
Women: WC ≥ 80 cm Women: WC > 88 cm  
Microalbuminuria Urinary albumin 
excretion rate ≥20 
mg/min or albumin: 
creatinine ratio ≥30mg/g 
   
Table 1: Comparison of four different MetS definitions [ALBERTI et al. 2006]. 
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2.2. Pathophysiology of the Metabolic Syndrome  
 
The pathogenesis of each of the MetS components is complex and until now 
not fully elucidated. Therefore the syndrome as a whole, which means the 
interplay of all the single components, remains to be an interesting subject for 
research. Various factors, e.g IR, genetic profile, physical inactivity, hormonal 
dysregulation, etc., have been proposed to be causal factors for development 
of MetS. In the following subchapters the most important factors that have 
been associated with the cluster of diseases are explained. 
2.2.1. Obesity 
 
Obesity is a condition of excess body fat and is currently defined by using 
body mass index (BMI), WC and/or WHR [HILL et al. 2006].  
 
BMI is calculated as weight (kg)/ height squared (m2) and is independent of 
sex and also age in adults. Subjects with a BMI in the range of 25 to 30 are 
considered as overweight and those with a BMI of 30+ as obese 
[GALLAGHER et al. 2000]. This parameter is a suitable but not perfect 
surrogate for body fatness as there are individuals who are overweight but 
have a normal amount of body fat. This appears e.g. in bodybuilders that 
have a large muscle mass, which is accountable for the high weight. On the 
other hand there are also people with a normal BMI that have high body fat 
percentage but reduced muscle mass. Measuring the WC or WHR could be 
an additional check [HILL et al. 2006] for the correct identification of 
individuals. WC is highly correlated with the amount of visceral fat, which, in 
many studies, has been shown to increase risk for diabetes, hypertension, 
dyslipidaemia and ischemic heart disease [KISSEBAH et al. 1982]. The WHR 
is used to make a difference between the benign pear shaped and the malign 
apple shaped overweight individuals but, on its own, it does not represent 
obesity [HENNEMAN 2010]. 
 
Next to sedentary lifestyle and unhealthy nutrition it is suggested that genetic 
factors may play an important role in determining the response of body mass 
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and body fat stores to chronic alterations in energy balance [PERUSSE and 
BOUCHARD 2000]. Family studies show strong genetic influences on body 
weight. MAES et al. (1997) estimated in their review that up to 80% of 
variation in BMI is explained by genetic factors. But these results have to be 
looked at with great caution as it is often not clear where genetics end and 
environmental influence, in this case e.g. sharing the same food or the same 
exercise habits within a family, starts. 
2.2.2. Insulin resistance 
 
In a normal physiological state insulin increases glucose uptake by peripheral 
organs such as muscle and fat and suppresses glucose production by the 
liver [HENNEMAN 2010]. If IR, which is defined as “a decreased response of 
the peripheral tissues to insulin action” [XU H. et al. 2003], is present, insulin 
is not able to act normally in the regulation of nutrition and metabolism and 
therefore plasma levels have to be increased to achieve normal plasma 
glucose levels. If levels of fasting plasma glucose consistently rise up to 7 
mmol/L it can be said that the person has T2D [AMERICAN DIABETES 
ASSOCIATION 2007]. This appears when the increased insulin secretion 
cannot compensate for the decreased response of the tissues anymore. The 
glucose homeostasis cannot be maintained – resulting in cytotoxic 
hyperglycaemia [HENNEMAN 2010]. 
 
Free fatty acids (FFA) have been shown to be a major link between obesity 
and IR [BODEN 2004]. FFA inhibit insulin-stimulated glucose uptake at the 
level of glucose transport and/or phosphorylation through mechanisms that 
involve accumulation of diacylglycerol and long-chain acyl-CoA activation of 
proteinkinase C and decreased tyrosine phosphorylation of insulin receptor 
substrate 1/2 (IRS-1/2) [BODEN et al. 2005]. FFA concentrations can be 
reduced by a small increase in insulin levels. That means that high plasma 
FFA concentrations can be prevented if large amounts of insulin can be 
secreted. If this does not happen high FFA concentrations increase hepatic 
glucose production, which is likely to lead to significant fasting hyperglycemia 
[REAVEN 1988]. 
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2.2.3. Dyslipidemia 
 
Dyslipidemia is a condition that shows no symptoms by itself but leads to 
symptomatic vascular disease. It is a disorder of lipoprotein metabolism, 
which is characterized by three major components: increased fasting and 
postprandial triglyceride-rich lipoproteins, decreased HDL and increased low-
density lipoprotein (LDL) particles [RUOTOLO and HOWARD 2002]. 
 
Reasons for dyslipidemia can be diverse. Genetic, but especially lifestyle 
factors are proposed to have a big influence. Living a sedentary lifestyle with 
excessive food intake leads to hyperlipidemia, the most common form of 
dyslipidemia, which plays a major role in the development of atherosclerosis 
[MATSUZAWA et al. 2004]. But hyperinsulinaemia and central obesity also 
have a great impact on it as they lead to overproduction of very low-density 
lipoproteins (VLDL) [HOWARD 1999], which are interacting with other 
lipoproteins and therefore disturbing the metabolic balance. 
 
As cardiovascular diseases are the number one cause of death in many 
countries, the management of dyslipidemia forms an important part of the 
strategies for their prevention [THOMPSON 2004]. To calculate the risk for 
each person individually the FRAMINGHAM HEART STUDY developed an 
algorithm, the Framingham Risk Score, which estimates the risk of various 
cardiovascular diseases. It uses age, gender, total cholesterol, HDL 
cholesterol, smoker/non smoker and systolic blood pressure, among others, 
as parameters for the assessment. 
 
At the moment there are two ways of classifying dyslipidemia. One is by 
aetiology and one by phenotype. As genes are always affected by lifestyle 
and nutrition the first classification can be a problematic one. Nevertheless, 
common variants have been found at 30 loci that contribute to polygenic 
dyslipidemia [KATHIRESAN et al. 2009]. FREDERICKS and LEES 
developed a classification by phenotype in 1965. They used paper 
electrophoresis to separate lipoprotein groups and then arranged them into 
five different groups. More details on that topic were excluded, as they are 
not necessary for this thesis. 
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2.2.4. Hypertension 
 
Hypertension is a condition of constantly elevated blood pressure (BP). It is a 
major risk factor for coronary heart disease, stroke, congestive heart failure, 
renal insufficiency and peripheral vascular disease [BURT et al. 1995]. There 
are indications that MetS components like hyperglycemia or systemic 
inflammation affect the functioning of the vascular endothelium and therefore 
have an influence on the blood pressure [HENNEMAN 2010].  
 
Nutritional factors, e.g. high salt intake, obesity and insulin resistance have 
been shown to increase the BP but genes have been discussed to be 
involved in the development of hypertension, too. At least 10 genes have 
been shown to raise or lower BP by increasing or decreasing salt and water 
reabsorption by the nephrons [CARRETERO and OPARIL 2000]. 
 
The Seventh Report of the Joint National Committee on Prevention, 
Detection, Evaluation and Treatment of High Blood Pressure, which was 
done in 2003 by the National High Blood Pressure Education Program 
(NHBPEP) estimates that hypertension affects approximately 1 billion people 
worldwide with an upward trend. All of these individuals can be classified into 
groups by level of their BP: normal blood pressure, pre-hypertension, 
hypertension and hypertension stages I and II. For the MetS definition a BP 
of ≥ 140/90 mmHg (EGIR, WHO) or ≥ 130/85 mmHg (NCEP ATP III, IDF), 
respectively, is needed to be considered as hypertension. 
2.2.5. Inflammation 
 
Inflammation is a response of the vascular tissue to infection, irritation or any 
other injury. In this way the body tries to get rid of pathogens and to initiate 
the healing process. Acute inflammation is crucial for wound healing but if it 
turns into chronic inflammation it is dangerous and painful. Instead of healing 
it damages the healthy organs and can lead to various diseases like 
atherosclerosis, rheumatoid arthritis or inflammatory bowel disease [THEWS 
et al. 1999]. 
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This happens because lowgrade systemic inflammation is damaging the 
endothelium, leading to endothelial cell dysfunction and abnormal blood 
pressure regulation. When the endothelial barrier function is not working 
properly, harmful substances, like LDL, can enter into the sub-endothelial 
space. A chronic accumulation and oxidation of LDL as well as an uptake of 
invading macrophages leads to foam cell formation, which is considered to 
be the first step of atherosclerotic plaque [THEWS et al. 1999]  
 
Although it is not part of any of the explained definitions, inflammation, as a 
fifth component of MetS, is also included in this thesis. The reason is that 
inflammation has been shown to play an important role in developing CVD 
and T2D [HAFFNER 2006]. An 8-year follow-up of 14.719 initially healthy 
women, which was conducted by RIDKER et al. (2003), showed that 
elevated levels of the inflammatory marker C-reactive protein (CRP) are 
associated with increased risk for CVD and T2D, but also with fasting insulin 
and microalbuminuria. Although it is not included in any of the definitions, 
CRP measurements would add important information for easier identification 
of patients with MetS. 
 
In general it can be said that MetS is an equation with various unknown 
parts. Inaccurate definitions or unreliable parameters make it hard to answer 
the question of how many people are really affected by MetS. 
2.3. Prevalence 
 
Talking about prevalence of MetS is almost impossible. As mentioned above, 
different definitions not only make it uneasy to compare individual studies but 
also make it hard to give exact numbers of prevalence. Looking at the table, 
the cut-off points and the combination of components do not seem to have 
large scale variations but when seen graphically the degree of disparity in 
diagnosing MetS can be seen.  
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The DECODE Study Group 
[2005] compared the three 
definitions with each other in a 
cohort group of 9140 non-
diabetic European subjects 
(4190 men and 4950 women). 
The graphic that they generated 
out of their collected data shows 
that there is a poor agreement 
between the definitions. There 
are 34% of the women (31% of 
men, data not shown in figure 1) 
who meet all the three definition 
criteria. It shows furthermore that 
39% of the whole female subjects (37% of the men) meet only one definition. 
The definition by NCEP ATP III had the highest MetS prevalence identifiying 
76% of the subjects as affected with MetS in comparison to EGIR, which 
identified 54% as affected (WHO: 64%) [DECODE STUDY GROUP 2005]. 
 
A study in Pudong, new area of SHANGHAI, collected data of 5583 subjects 
(2477 males and 3107 females) and compared the NCEP ATP III, the WHO 
and IDF definition with each other. Although 69% of the men and 64% of the 
women were classified as being free of MetS only 9% of men and 13% of 
women met all of the three definition criteria. In this study the NCEP ATP III 
data showed prevalence for MetS of 28% in men and about 35% for women 
[XU et al. 2010]. 
 
In the USA, FORD et al. (2002) conducted a study on MetS prevalence using 
NCEP ATP III criteria. They showed that of 4265 men 22% and of 5356 
women 24% have MetS, also emphasizing the age of the subjects. Because 
44% of men and 42% of women in the 60+ years category have MetS it is 
evident that age is an important risk factor, which is very alarming. XU et al. 
(2010) namely mention in their study that the age group 60+ accounts for 
Figure 1: Comparison of the MetS definitions by 
prevalence [DECODE STUDY GROUP, 2005] 
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more than 20% of overall residents of the city. And in almost all developed 
countries the same tendency can be seen. 
 
In Europe HU et al. (2004) collected data of 6156 men and 5356 women and 
evaluated them by WHO criteria with the result that 16% of men and 14% of 
women have MetS, which may indicate lower prevalence than in China or the 
USA. But no exact comparison can be made because of different definitions 
criteria. 
 
Although there are problems because of the inability of comparison between 
the definitions still some conclusions can be made. There is a high 
prevalence of MetS, especially in elderly people. Because the average age is 
constantly rising, the appearance of MetS will increase in the future. The 
ongoing nutrition transition and sedentary lifestyle retrieve big potential risks 
for development of MetS, also in young people. So for the future, further 
research is needed for new therapies, as lifestyle changes are not easy to 
achieve. Among others, adipose tissue hormones have showed promising 
results. 
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3. Adipose tissue and its bioactive peptides 
 
There are different forms of adipose tissue. In general it can be divided into 
white adipose tissue (WAT) and brown adipose tissue (BAT). In the scope of 
this work only the first one is considered. It represents the majority of adipose 
tissue in the organism. Although it consists of numerous cell types, 
adipocytes are the prevailing one [FANTUZZI 2005]. WAT again can be 
divided into two subgroups, visceral and subcutaneous fat, by the place 
where it accumulates (apple-shaped, pear-shaped). In terms of adipocytokine 
production it is important to know that subcutaneous fat and visceral fat are 
not equivalent. Visceral fat is likely to have a much more direct signalling and 
metabolic relation with the liver in comparison to subcutaneous fat because it 
drains directly into the portal vein [HENNEMAN 2010]. 
 
For a long time WAT was considered to be only energy storage. But the 
identification of its ability to secrete bioactive peptides, which function as 
hormones, established the tissue as an endocrine organ. Until now it has 
been shown that adipose tissue has various responsibilities in the human 
body. It stores triglycerides, responds to nutrient, neural and hormonal 
signals and secretes adipocytokines that control energy homeostasis, 
thermogenesis, immunity and neuroendocrine function [KERSHAW and 
FLIER 2004]. Two of these adipocytokines are leptin and adiponectin, which 
are the focus of this thesis.  
 
There is a controversial discussion what leptin and adiponectin actually are 
because they cannot be exactly classified. Suggested groups are 
adipocytokines, cytokine-like hormones and adipose derived hormones. The 
problem is that the differences between hormones and cytokines diminish the 
more it is known about them. To simplify matters, in this thesis, the term 
adipocytokines will be used. But it is important to know that there are different 
names when searching for information in databases. Generally, 
adipocytokines are defined as biologically active polypeptides that are either 
exclusively or substantially produced by adipocytes and act by endocrine, 
paracrine and autocrine mechanisms [ROSE et al. 2004]. 
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As already mentioned the focus of the thesis is on leptin, adiponectin and 
their receptors. To show their relation to MetS it is essential to know the 
biochemistry behind it. Therefore they are explained in the following 
subchapters – from the structure to the signalling. 
3.1. Leptin 
 
In 1994 ZHANG et al. discovered a murine obese (OB) gene that is 
responsible for obesity in the ob/ob mouse. Shortly after, the gene was 
located on chromosome 7 (7q31.3) in humans. Also known as LEP, OBS or 
FLJ94114 [NCBI Entrez Gene 2010], OB was found to encode a protein, 
leptin, which has been in the focus of nutrition science ever since. 
 
Leptin is a 16 kD protein that is built of 167 amino acids [KERSHAW and 
FLIER 2004]. These are arranged in four α-
helices (see figure 2), which make it look 
similar to interleukin-6 (IL-6). Therefore, 
structurally, it belongs to the type-1-cytokine 
superfamily [LA CAVA and MATARESE 2004]. 
The main source of leptin is adipose tissue 
although it is also secreted by e.g. the gastric 
epithelium, skeletal muscle and placenta 
[AHIMA and OSEI 2004].  
 
Leptin has been shown to be an anorexic peptide that is responsible for the 
regulation of satiety, hunger and energy homeostasis [OTERO et al. 2006]. 
Low levels of leptin enhance appetite and decrease energy utilization by 
initiating endocrine starvation response (see also figure 3) [BATES and 
MYERS 2004]. Therefore it was expected that leptin may be a good 
treatment for obese individuals.  
Although significant effects have been shown in ob/ob mice, the effect in 
obese humans failed because leptin deficiencies are not common in human 
obesity [TARTAGLIA 1997]. In contrast, obese individuals showed increased 
levels of leptin leading to the conclusion that this hormone serves more as a 
Figure 2: The four α-helices of 
leptin [VOSS 2007] 
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signal of energy sufficiency rather than energy excess, and therefore 
resistance to leptin may be more important than increased or decreased 
levels [BATES and MYERS 2004]. Consequently, attention was paid to the 
leptin receptor and the appropriate LEPR gene, pushing the db/db mouse, a 
model of complete resistance, into the spotlight.  
 
Other causes that lead to non-activity of leptin have also been suggested. It 
has been linked to decreased transport across the blood brain barrier (BBB), 
which is due to a deficit in short leptin receptor isoforms, but also to 
desensitization for the leptin signal [OTERO et al. 2006].  
 
 
 
Figure 3: Effects of Leptin in the human body [LaCAVA and MATARESE 2004] 
3.2. Leptin receptor 
 
As mentioned above, with time, leptin resistance got more important than the 
increased or decreased levels of leptin itself. The db/db mice were chosen 
because they showed early onset obesity like the ob/ob mice and indicated 
defects in reception of leptin. It was suggested that the db gene encodes 
either the gene for the leptin receptor or a gene that is encoding an important 
	   16	  
component of the leptin signalling pathways [TARAGLIA et al. 1995]. Further 
studies revealed that there is a mutation in the db gene that can be made 
responsible for the leptin resistance. In exon 12 of the LEPR gene a G 
residue is deleted. So the initial sequence AAGGAG turns into AAGAG. It is 
impossible to say if the nucleotide 2022 or 2023 was deleted but the change 
causes a substitution of 11 amino acids. As a result, the intracellular domain 
of the protein is cut [TARTAGLIA 1997; BROWN et al. 2000]. 
 
LEPR has been assigned to the class-I-cytokine receptors. It is closely 
related to gp130, a protein of the IL-6 signalling complex, the leukaemia 
inhibitory factor receptor and the granulocyte colony stimulating factor 
receptor [TARTAGLIA et al. 1995]. Until now at least 5 LEPR isoforms have 
been described and labelled from LEPRa to LEPRe [BJOERBAEK and 
KAHN 2004]. They all share an identical N terminal ligand-binding domain, 
which is the extracellular domain, but differ in the C terminal (intracellular) 
region because of the alternative RNA splicing at the most C-terminal coding 
exon [TARTAGLIA 1997]. 
 
The intracellular domains of LEPR a, c and d are about 30 to 40 amino acids 
long [BANKS et al. 2000]. Therefore they have no signal transducing 
capabilities and are called “short receptors”. In general their levels in human 
tissue are much higher than those of LEPRb, with only one exception - the 
hypothalamus. Their exact functional roles and the differences among the 
various forms remain to be defined. It is suggested that they are important for 
carrying leptin from the blood into the cerebrospinal fluid, from where the 
adipocytokine can diffuse to the brain centres and perform its functions. It is 
also proposed that they could be responsible for clearance or as a source of 
soluble receptor [TARTAGLIA 1997]. 
 
LEPRe is the shortest receptor of the group, because it is truncated. It 
contains only the coding regions for extracellular domains, meaning, it does 
have neither the transmembrane nor the intracellular domain. So LEPRe 
functions as a soluble leptin-binding protein [AHIMA and OSEI 2004]. 
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Last but most important is LEPRb, also called the “long receptor”, that is build 
out of 1162 amino acids [LA CAVA and MATARESE, 2004]. Its C-terminal 
region exists of about 300 amino acids, which is almost ten times longer than 
the one of the short forms. LEPRb is the only leptin receptor that has 
intracellular tyrosine residues and therefore is the only isoform capable of 
activating a signal transduction [BANKS et al. 2000]. It can be detected in 
several peripheral tissues but at much lower levels compared to LEPRa. It 
has been measured in lung, kidney, adrenals and lymph nodes and at lower 
levels in liver, BAT, WAT, and skeletal muscle. The account of LEPRb is 
under 5-10% of total leptin receptor expression [BJORBAEK and KAHN 
2004]. 
 
There are various signalling effects that can emanate from LEPRb when 
leptin binds to it. Four of them are mentioned in this thesis: The JAK (janus 
activating kinase)/STAT (signal transducer and activator of transcription) 
pathway, the p38 mitogen-activated protein kinase (p38 MAPK) and 
phosphatidyinositol 3 kinase (PI3K) pathway as well as the adenosine 
monophosphate kinase (AMPK) pathway [ZHANG et al. 2005]. In the leptin 
signalling chapter the JAK/STAT pathway is explained in detail, as it is the 
best-known one. P38 MAPK and PI3K are only shortly mentioned. The 
AMPK pathway is explained in more detail in the adiponectin signalling 
chapter. 
3.3. Leptin signalling 
 
LEPRb is a protein with a fibronectin type III domain and a block of amino 
acids in the extracellular region. This block contains four conserved cysteine 
residues and two cytokine-like binding motifs - Trp- Ser- Xaa- Trp- Ser 
(WSXWS) (see figure 4) [LA CAVA and MATARESE 2004; AHIMA and OSEI 
2004].  
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When Leptin binds to the receptor the “box1” motif recruits cytoplasmic JAK2 
[FRÜHBECK 2006]. It binds to the box resulting in its activation, which leads 
to tyrosine phosphorylation. There are four phosphorylated tyrosine residues 
(Tyr974, Tyr985, Tyr1077, Tyr1138) on LEPRb that function as docking sites 
for proteins with Src homology 2 (SH2) domains like STATs [La CAVA and 
MATARESE 2004; LÖFFLER 2005]. 
 
Tyr1138 functions as a docking site for 
STAT3. When STAT3 binds to that site it 
becomes phosphorylated by JAK2. After 
phosphorylation STATs dissociate into the 
cytoplasma and form dimers. In that form 
these dimers can translocate into the 
nucleus and induce the expression of the 
suppressor of cytokine signalling 3 
(SOCS3) and other genes. SOCS3 binds 
to the phosphorylated tyrosines (Tyr 1077 
in figure 4) and therewith blocks the leptin 
signalling. A second negative regulator of 
leptin signalling is phosphotyrosine 
phosphatase 1B (PTP1B). It 
dephosphorylates JAK2, which is then 
incapable of activation of the signalling 
pathway. PTP1B is actually a physiological insulin receptor phosphatase, 
also functioning as a negative regulator of insulin signalling, which shows the 
proximity of the pathways [LA CAVA and MATARESE 2004; BJORBAEK and 
KAHN 2004]. 
 
Tyr985 and Tyr974 recruit SH2 domain-containing phosphatase 2 (SHP2). 
This phosphorylates the growth factor receptor-bound protein 2 (GRB2), 
which is then able to activate extracellular signal-related kinase 1/2 (ERK 1/2) 
and p38 MAPK cascade over Ras/Raf. In the end of the signalling, the 
expression of Fos and Jun is induced [LA CAVA and MATARESE 2004; 
BJORBAEK and KAHN 2004; FRÜHBECK 2006] 
Figure 4: Leptin signalling [LaCAVA et 
MATARESE, 2004] 
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JAK2 induces the phosphorylation of IRS 1/2 proteins that activate the PI3K 
pathway [LaCAVA et MATARESE 2004; LÖFFLER 2005]. As IRS is also 
used by insulin signalling, it represents the point of crosstalk between leptin 
and insulin. 
 
As already mentioned the AMPK pathway is explained in more detail in the 
adiponectin signalling part. The only thing to be mentioned is that leptin 
decreases AMPK activity in the hypothalamus, which leads to reduced 
appetite and increased peripheral fatty acid consumption. Negative energy 
balance and reduction in body weight are the results [LIM et al. 2010]. 
3.4. Adiponectin 
 
The adipocytokine adiponectin is also called GBP-28 (gelatin binding protein 
of 28kDa), apM1 (adipose most abundant gene transcript 1), AdipoQ or 
Acrp30 (adipocyte complement-related protein of 30 kDa) [KERSHAW and 
FLIER 2004]. It is encoded by the ADIPOQ gene, which is located on 
chromosome 3 (3q27) [NCBI Entrez Gene, 7.6.2010]. Since it has been 
characterized in 1995/1996, adiponectin has been in the focus of interest as 
it has shown possible therapeutic effects for metabolic disorders [YOON et 
al. 2006]. 
 
It is an approximately 30 kDa polypeptide, made of 244 amino acids, that has 
a N-terminal signal sequence, a variable domain, a collagen-like domain and 
a C-terminal globular domain [KERSHAW and FLIER 2004]. In contrast to 
leptin it is specifically and highly expressed in human adipose cells. 
Adiponectin belongs to the soluble defence collagen superfamily, as it has 
structural homology to collagen VIII and X as well as complement factor 1q 
[DIEZ and IGLESIAS 2003]. Existing in a wide range of multimer complexes 
in plasma, it combines itself via its collagen domain to create 4 major 
oligomeric forms. It appears as a trimer (globular form), a trimer with a low 
molecular weight (LMW), a hexamer with medium molecular weight (MMW) 
and a 12 to 18-mer high molecular weight form (HMW) [KADOWAKI et al. 
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2006]. With levels of 5-30 µg/ml it is abundant in human plasma [DIEZ and 
IGLESIAS 2003]. 
 
An exact physiological role for adiponectin has not yet been established but 
hypoadiponectinaemia has been associated with MetS more than any other 
inflammatory marker [KADOWAKI et al. 2006]. In contrast to leptin, it has 
been shown that adiponectin is negatively regulated in obesity, T2DM and 
coronary artery disease, leading to the opinion that this protein has anti-
atherogenic and insulin-sensitizing effects [DIEZ and IGLESIAS 2003]. 
Adiponectin is able to increase tissue fat oxidation. Through that it can 
reduce the amount of circulating fatty acids, which leads to increased insulin 
sensitivity. Furthermore it suppresses the cytokine production from 
macrophages and the expression of adhesion molecules in vascular 
endothelial cells, which results in the inhibition of the inflammatory process. 
Therefore it has been concluded that adiponectin also has anti-inflammatory 
effects [DIEZ and IGLESIAS 2003].  
 
Although it is not known how estrogen and testosterone influence adiponectin 
levels it has been shown that they are, like leptin, gender-dependent. Studies 
have reported higher levels in women than in men [DIEZ and IGLESIAS 
2003] which might make women more insulin sensitive than men and lower 
their risk for cardiovascular diseases. How adiponectin exactly works is not 
fully elucidated. It is known that it activates the AMPK pathway, which 
increases glucose uptake as well as fatty acid oxidation rates and that it 
stimulates the peroxisome proliferator activated receptor α (PPARα), which 
promotes lipid oxidation. These effects are dependent from relative 
circulating concentrations and different isoforms of adiponectin [KERSHAW 
and FLIER 2004], but also of its receptors [BEYLOT et al. 2006], which are 
explained closer in the next section.  
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3.5.   Adiponectin receptor 
 
Two transmembrane domain-containing proteins, which are encoded by 
genes on chromosome 1 (1q32) and 12 (12p13) have been identified as 
adiponectin receptors and named AdipoR1 and AdipoR2. However, these 
two are not like the usually G-protein-coupled receptors (GPCR), as they are 
structurally and functionally distinct from them. AdipoR have the N-terminus 
within the cell. Therefore adiponectin has to interact with the C-terminus, 
which is opposite to the normal GPCRs [MAO et al. 2006]. Another argument 
showing that these receptors are not GPCRs is that overexpression of 
AdipoR1 and AdipoR2 has little effect on cyclic adenosine monophosphate 
(cAMP), cyclic guanosine monophosphate (cGMP) and intracellular calcium 
levels [KADOWAKI et al. 2006].  
 
AdipoR1 is primarily expressed in skeletal muscle and functions there as a 
high-affinity receptor for globular adiponectin and as a low-affinity receptor for 
full-length HMW-adiponectin. AdipoR2, in contrast, is primarily expressed in 
liver where it functions as an intermediate-affinity receptor for both, globular 
and full-length HMW adiponectin [TAKEUCHI et al. 2007]. Both of them 
activate sets of signalling molecules such as PPARα, AMPK and p38 MAPK, 
glucose uptake and fatty oxidation [KADOWAKI et al. 2006]. 
 
As a third receptor T-cadherin, which belongs to the cadherin (calcium 
dependant adhesion molecules) superfamily, has been characterized. It is a 
unique member of that group as it lacks the transmembrane and the 
cytoplasmic domain. T-cadherin is only anchored to the surface membrane 
via a glycosyl phosphatidyl inositol part. As it has no intracellular domain, it is 
thought that it has no effect on adiponectin cellular signalling. Nevertheless it 
is able to bind it [KADOWAKI et al. 2006] – its hexamer and HMW isoforms in 
particular [HUG et al. 2004]. 
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3.6. Adiponectin signalling 
 
Adiponectin signalling differs substantially from the biochemical pathway of 
leptin because the constitutions of the receptors are unequal. As mentioned 
above, it is not known if T-cadherin has any signalling effects and therefore it 
is not explained any further in this thesis. For the other two receptors 
(AdipoR1 and AdipoR2) various pathways are suggested and explained (see 
figure 5). 
 
 
Figure 5: Structural forms of adiponectin and their ways of signalling [KADOWAKI et al. 
2006] 
Adiponectin is considered a starvation hormone. During fasting conditions 
high levels of adiponectin are present, which stimulate central and peripheral 
AMPK, leading to increased food intake and decreased energy expenditure 
[LIM et al. 2010]. When adiponectin binds to the extracellular C-terminus of 
the receptor, APPL1 (adaptor protein containing pleckstrin homology domain, 
phosphotyrosine-binding domain and leucin zipper motif) is recruited to the 
intracellular N-terminus [MAO et al. 2006]. It is not known how APPL1 
activates AMPK, p38 MAPK and Rab5, but it does [DEEPA and DONG 
2009]. In this chapter only the AMPK is explained.  
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If AMPK is activated, adenosine triphosphate (ATP)-consuming processes 
are shut down for energy saving and catabolic processes are activated to 
generate ATP [DEEPA and DONG 2009]. In general it can be said that 
AMPK plays a key role as regulator of cellular energy homeostasis (see 
Figure 6). It has an influence in the carbohydrate, lipid and protein 
metabolism and therefore defects in the signalling pathway might play a big 
role in the MetS. E.g AMPK inactivates 3-hydroxy-3-methlygluataryl (HMG) 
CoA reductase as well as acetyl CoA carboxylase (ACC), which are the key 
enzymes of fatty acid and cholesterol synthesis [LIM et al. 2010]. A decrease 
in ACC activity reduces intracellular malonyl-CoA levels and stimulates 
carnitin palmitoyl transferase 1 (CPT1), which increases the influx of long 
chain fatty acids into the mitochondria, where they are oxidized [YOON et al. 
2006]. 
 
 
Figure 6: AMPK signalling. [Cell Signaling Technology 2010] 
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It is clear that little changes in the signalling pathways as well as defects on 
genes encoding every single parameter might play a significant role in the 
development of the diseases. Searching for single changes in the DNA that 
have an effect on the functioning of leptin and adiponectin is the main topic of 
this thesis. How researchers find these polymorphisms is explained in the 
following chapter. 
	   25	  
4. Genome-wide association studies 
4.1.  Definition and advantages 
 
“Genome wide association studies (GWAS) use high throughput genotyping 
technologies to assay hundreds of thousands of single nucleotide 
polymorphisms (SNPs) and relate them to clinical conditions and measurable 
traits” [PEARSON and MANOLIO 2008].  
 
Candidate gene association studies and linkage analysis have been the past 
methods of genetic studies. In contrast to GWAS they are more restricted. 
For candidate gene association studies it was a precondition to have an idea 
which genes could have an effect on e.g. the disease development. Linkage 
studies, on the other hand, had the advantage that genes could be identified 
without known functional connection to disease. However, they lack statistical 
power to detect quantitative trait loci (QTL). Furthermore they were 
performed in families, which means that unrelated individuals could not be 
compared. GWAS, in contrast, can be performed in unrelated individuals and 
there is also no need to know the biological function in advance [FARBER 
and ROSEN 2010].  
 
Also in the case of non-Mendelian conditions, GWAS aroused to be better 
than family based linkage studies. GWAS have higher power for complex 
disorders that are influenced by multiple genes and the large size of the 
chromosomal regions shared between family members [PEARSON and 
MANOLIO 2008]. When GWAS result in novel loci, the “candidate gene” 
approach is generally chosen to search for and validate the causal variant 
[HENNEMAN 2010]. 
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4.2.  History 
 
Until 2005 a few “early versions” of GWAS have been performed and 
published. A study by OZAKI et al., which was accomplished in 2002, is 
considered to be the first large genome-wide study. Nevertheless, a GWAS 
by KLEIN et al. (2005), showing that age related macular degeneration 
associates with variation in the gene for complement factor H, is registered 
as the first study in the National Human Genome Research Institute (NHGRI) 
Catalogue of Published Genome-Wide Association Studies [HINDORFF et al. 
2010]. The reason therefore is that KLEIN et al. (2005) were the first ones to 
use microarray technologies instead of high throughput multiplex PCR-
Invader assay methods. And they also used random selection of SNPs, 
covering genes and intergenic regions instead of only focusing on gene-
based SNPs that were randomly selected from a gene-based SNP discovery 
study [KU et al. 2010]. 
 
The breakthrough for GWAS was the completion of the International HapMap 
project (phase I in 2005 and phase II in 2007). That project was a multi-
country effort to validate millions of SNPs, to characterize their correlation or 
linkage disequilibrium patterns in populations of European, Asian and African 
ancestry and to establish a catalogue of common genetic variants that 
appear in human beings. This catalogue describes “what these variants are, 
where they occur in our DNA and how they are distributed among people, 
within populations and among populations in different parts of the world”. 
[International HapMap Project 2010]. After the publishing of the HapMap 
project the number of performed GWAS exploded and a huge amount of 
data, which has to be dealt with, has been generated ever since. GWAS 
represent a powerful new tool for identification of genes that are influencing 
common diseases but also lead to new terminologies. Most important ones 
are explained below as well as the statistical terms that are used. 
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4.3. GWAS basics 
4.3.1. Single nucleotide polymorphisms  
 
The most important abbreviation in GWAS is SNP, which stands for single 
nucleotide polymorphism. Every time the DNA replicates itself it makes a 
couple of mistakes, which are classified into three different groups: bad 
mistakes, good mistakes and indifferent mistakes [BRODY 2007]. Although 
99.9% of the mistakes have no effect (indifferent mistakes) there is this 0.1% 
part that, nevertheless, represents millions of mistakes among 3.2 billion 
base pairs that have an effect and are looked at accurately, because they 
might be the cause of disease or health [KRUGLYAK and DICKERSON 
2001].  
 
Single Nucleotide Polymorphisms are 
the most common “mistakes” in the 
human genome [RAMENSKY et al. 
2002]. To be put into that category the 
variation has to occur in, at least, 1% 
of the population and has to be stable 
- otherwise it is called a mutation 
[KRUGLYAK and DICKERSON 2001]. 
 
SNPs occur when the genome 
sequence is altered. As mentioned 
above the biggest portion of the bases 
match but from time to time there are 
variants where a single nucleotide (A, T, C or G) in the genome sequence is 
altered and the DNA sequence is changed e.g. from CTA to TTA (see Figure 
7). These variations happen due to replication error and imperfect DNA 
repair. They appear approximately in 1 out of 1000 bases. That leads to the 
estimation that 20 to 30 millions of different variable sites exist in the 
population but not all of them are common [BRODY 2007].  
 
Figure 7: Single nucleotide polymorphism 
[SCIENCE MARSHALL 2010] 	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Generally SNPs can be divided into two groups – the non-synonymous and 
the synonymous SNPs. Synonymous SNPs have an altered nucleotide but 
still encode the same amino acid. E.g. the sequences GGG and GGC both 
encode the amino acid glycin. But if a polymorphism results in a change in 
the amino acid sequence of a protein and therefore changes its function, it is 
called a nonsynonymous SNP [PEARSON and MANOLIO 2008]. If there is a 
non-synonymous SNP, the impact on the phenotype is much higher than of 
synonymous ones [RAMENSKY et al. 2002]. 
  
As there are huge numbers of SNPs it was needed to develop a database to 
keep them organised. Almost 12 million human SNPs were assigned a 
reference SNP (rs) number in the dbSNP database of the National Center for 
Biotechnology Information and characterized as to specific alleles (alternate 
forms of SNPs), summary allele frequencies and other genomic information 
[PEARSON and MANOLIO 2008]. In the results chapter the rs numbers are 
used when they are known. If not, it was referred to the old descriptions 
where instead of the number (rs7799039) the correspondent marker is used 
(G2548A).  
4.3.2. Linkage disequilibrium 
 
Linkage disequilibrium is defined as 
“association between two alleles 
located near each other on a 
chromosome, such that they are 
inherited together more frequently 
than expected by chance” 
[PEARSON and MANOLIO 2008]. 
This means that variations are 
inherited in groups, which is very 
important for GWAS (especially in 
terms of time and costs) because it 
significantly reduces the number of 
SNPs that need to be genotyped [KU 
Figure 8: Linkage disequilibrium plot of the 
ARL15 gene [RICHARDS et al. 2009] 
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et al. 2010]. Consequently one SNP can be used as a proxy for others, which 
is the concept of tag SNPs [MANOLIO 2007]. 
 
R2 or D´ express the correlation between SNPs. Both represent the 
proportion of variation of one SNP explained by the other. The results range 
from 0 (no association, which are the blue areas in figure 8) to 1 (perfect 
correlation, which are the red areas in figure 8) [PEARSON and MANOLIO 
2008]. To simplify the display, association statistics are typically shown as 
the –log10 of the p-value of each SNP versus its chromosomal location, also 
called the “Manhattan” plot (upper part of figure 8).  
 
The degree of linkage disequilibrium can vary between populations. The 
further the SNPs are separated the less certain the relationships between 
them becomes. The distance can extend from hundreds to thousands of 
bases [BRODY 2007]. The blocks of identical genome sequences are shorter 
the less closely people are related. To say it the other way round: the blocks 
are long in identical twins where, in fact, the entire genome is the same 
initially. In siblings, parents and offspring the blocks are about 10 millions 
base pairs. GWA technology allows studies in unrelated people assuming 
that blocks of about 10000 base pair lengths are common [BRODY 2007]. 
4.3.3. Statistical terms 
 
Statistical knowledge is crucial to analyze GWAS. The most important terms 
are explained in this subchapter. The first to mention is the p-value, which 
stands for the probability of finding a result by chance alone. In the case of 
GWAS the conventional level of significance (p<0.05) would show that 50 
000 out of 1 million SNPs are associated with the disease, almost all falsely 
positive. To solve this problem the Bonferroni correction is applied. There the 
conventional p-value is divided by the tests performed. In the case of 1 
million SNPs a p-value of 10-8 (P=0.05/106) is needed to identify associations 
that are unlikely to be due to chance alone [PEARSON and MANOLIO 2008]. 
As the number of tested SNPs varies the p-values also alter. Recent studies 
just use probability values between 10-4 and 10-7 to minimize false 
association. The Bonferroni correction has been criticized because it 
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assumes that each SNP is independently associated with a disease but it is 
well known that some SNPs are in linkage disequilibrium [DING and KULLO 
2009]. 
 
Another measurement for linkage, which has nothing to do with LD, is the 
LOD score. LOD (logarithm of odds) estimates whether two loci are likely to 
lie near each other on a chromosome and are therefore likely to be inherited 
together as a package. A LOD score of three or more is generally taken to 
indicate that two gene loci are close to each other on the chromosome 
[DORAK 2010].  
 
If there are results the Odds ratio is always calculated. It stands for the 
approximate relative risk and measures the magnitude of the association 
between the disease and the sought polymorphism. In the case of GWAS, 
odds ratios are typically modest, often in the range of 1.2 to 1.3. If the 
disease is rare the odds ratio approximates the risk but always overestimates 
the effect [MANOLIO 2007]. Usually at least 1000 cases and 1000 controls 
are needed to detect ORs > 1.5 with at least 80% power. For ORs higher 
than 1.5 much larger sample sizes are needed. 
 
Hardy Weinberg equilibrium is a concept of stability of gene proportions in an 
ideal population. It explains the distribution of 2 alleles (with frequencies p 
and q) and their stable distribution from generation to generation as well as 
their genotypes that occur at frequencies of p2, 2pq and q2 for the major 
allele homozygote, heterozygote and minor allele homozygote respectively 
[HARDY 1908]. Although there is no ideal population, this concept is still 
practically used to detect genotyping errors. 
 
Replication studies are done as a test to exclude false-positive associations, 
but in GWAS, they often lead to failure of replication of the initial results. 
What also happens is the appearance of so-called flip-flop results. This 
means that an allele, initially protective, happens to be the risk allele in the 
replication study. Therefore all detected results have to be handled with care. 
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4.4. Genotyping platforms 
 
As mentioned shortly earlier in this thesis, GWAS use microarray technology 
for SNP detection. But the two commonly used brands, Affymetrix and 
Illumina, use different ways of approach. Illumina uses probes that are based 
on haplotype- tagging SNPs, which were identified in the HapMap project. 
Affymetrix arrays, in contrast, are for random SNPs that are chosen to cover 
the genome, supplemented by tagSNPs. The amount of tested SNPs is 
around 1 million. The Affymetrix‘s Genome Wide Human SNP Array 6.0 e.g. 
contains >906 000 SNPs [Affymetrix.com, Illumina.com]. 
 
The core of microarray technology is the preferential binding of 
complementary single stranded nucleic acid sequences. DNA microarrays 
are glass or silicone chips that consist of thousands of arrayed spots of 
specific DNA sequences, which are called probes. On these chips the target 
has to be applied. 
 
For easier comparison the way of functioning 
is explained in comparing diseased and 
healthy subjects. The first step is extracting 
the mRNA out of the cells of both 
populations, as it gives information about 
which genes are frequently read. With the 
help of mRNA the complimentary DNA 
(cDNA) can be reconstructed. In this case the 
healthy people are coloured green, the 
diseased ones red. Subsequently, the red 
and the green cDNA have to be mixed and applied on the platforms. As 
mentioned before every single spot on the chip is made of DNA and is able to 
build pairs with the cDNA, if they are complementary. This binding of probes 
and targets is called hybridization. If the two strands are absolutely 
complementary they will bind to each other readily. But if there are single 
inconsistencies they will make the binding less favourable or not bind at all. 
So on the chip there are spots that bind only the green cDNA, some only the 
red one, but some bind both of them [CAMPBELL 2001]. 
Figure 9: Microarray picture. 
[ANDERSON 2010]  
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Next step is washing the chip to remove all the cDNA that has not found a 
complementary strand and then to analyse it. The chip is scanned by a green 
and red laser, which reveals two individual pictures that are combined later 
on. The spots where the green cDNA has found her docking station are 
glowing in a green light and the landing places for the red cDNA are glowing 
in a red light. Spots that bound red and green cDNA appear as yellow dots 
(see figure 9) [CAMPBELL 2001]. From the combined picture it can be seen 
which genes are more expressed in diseased people or in the case of 
GWAS, which SNPs appear in unhealthy people but do not in healthy 
subjects. These are then tested for causation of the disease and/or to which 
part they play a role. 
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5. Literature research results 
 
The search for significant GWAS results was conducted by searching in the 
HuGe Navigator GWAS interrogator. This is a database that includes all the 
GWAS that have tested more than 100.000 SNPs in the initial stage and 
found SNPs with a p-value < 5x10-5. To fine-tune the query results a filter 
was used. In that way it was possible to limit the GWAS to the wanted gene. 
Disadvantages of this searching machine are the cut-off points. Not every 
GWAS tested more than 100.000 SNPs and therefore not every study 
needed a p-value < 5x10-5 to acquire significant results. So those studies are 
excluded in the Interrogator. SNPs that were probably close to the 
significance level are therefore not included although they might be 
important. To look for these “lost SNPs” PubMed was used as the main 
searching machine usually with specific catchwords, which are mentioned 
when used. Interesting SNPs, revealed from the studies, are looked one by 
one to search for further results e.g. through the NCBI Entrez SNP site or 
again PubMed. Common polymorphisms, reported not only by GWAS but 
also from different kind of studies were included as they show what has 
already been done and what results have been obtained until now. If studies 
that were used by researchers had a “short” name e.g. HYPEST 
(HYPertension ESTonia), it has been written that way. The meaning of the 
shortenings can be looked up in the list of abbreviations. Other used 
databases were Scopus and ScienceDirect but in most cases gave the same 
or less results than PubMed. The only database that gave the same or more 
results, but was to be treated with care, was Google Scholar.  
 
Generally an attempt was conducted to get full access to all the studies. As 
many of them are new (from 2009/2010), and were not even printed but 
published online, authors were asked for full access. Where it was not 
allowed abstracts were used. The same is valid for older studies, where full 
access was not granted. It was attempted to provide a complete overview of 
the topic but this thesis makes no claim to be complete. 
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5.1. LEP 
5.1.1. LEP – GWAS results 
 
The search for leptin polymorphisms with the GWAS interrogator revealed no 
hits, which means that none of the performed studies had tested more than 
100.000 SNPs and/or got significant results at a p-value level of <5x10-5 so 
far.  
 
Searching PubMed for further GWAS results with the keywords “genome-
wide association” and “LEP” yielded only one hit - a study searching for 
associations between polymorphisms and hypertension. It has been 
performed by SOBER et al. (2009) with the aim to see how well previously 
reported SNPs are represented on the arrays, as well as to find the 
polymorphism with the strongest signal for association. They included 5467 
participants from three different studies (KORA n=1644, HYPEST n=1823 
and BRIGHT n=2000) in which they analyzed SNPs from 160 genes that 
were connected to hypertension earlier on, for their association with blood 
pressure. Rs10954174 on the LEP gene has been associated with diastolic 
BP at a p-value level of 5.20x10-5 (see Table 2), which makes it not being 
significant for the GWAS Interrogator but coming quite close to the cut-off 
point. The search for further results for that particular SNP revealed no hits in 
other studies. 
5.1.2. LEP - Further results 
 
As there are no other GWAS results, outcomes from studies with other 
designs have been searched for too. Generally it has to be pointed out that 
these studies have declared their results as significant when reaching a p-
value<0.05. As only a few SNPs and/or smaller groups of people have been 
investigated, the general level of statistical significance may be enough.  
 
To continue the results from hypertension, combinations of the catchwords 
“leptin”, “polymorphism”, ”association” and “hypertension” have been used to 
find studies dealing with that topic. MA et al. (2009) have conducted a study 
	   35	  
searching for polymorphisms that are associated with SBP, DBP and plasma 
leptin levels. 29 SNPs within and around LEP were selected, 20 within the 
gene itself. 6 SNPs (rs13245201, rs7799039, rs6467166, rs12536535, 
rs10244329 and rs11763517) have shown associations with blood pressure/ 
hypertension but only in postmenopausal women. The search for more 
results on rs13245201 has shown no further hits, whereas rs7799039 has 
been mentioned by other studies (see below and Table 2). Rs6467166 has 
shown again no hits as well as rs12536535, rs10244329 and rs11763517. 
 
GANELHU et al. (2009) analyzed whether the rs7799039 polymorphism is 
associated with hypertension in 140 obese Brazilian women. Their findings 
have shown that the variant is linked to higher blood pressure levels and 
therefore might be an important mediator of hypertension in obese women. 
The same SNP has also been analyzed by BEN ALI et al. (2008) who have 
conducted a study where 229 Tunisian obese subjects were compared to 
251 Tunisian normal weight subjects with the aim to look for association with 
hypertension. As a result they have shown that rs7799039 is associated with 
blood pressure, but only in obese male patients.  
 
Studies dealing with associations of the LEP gene polymorphisms and 
obesity itself have been found in PubMed through the combination of 
catchwords “leptin”, “polymorphism”, ”association” and “obesity”. JIANG et al. 
(2004) have carried out a study looking for polymorphisms associated with 
BMI. They have genotyped 29 SNPs within (20 SNPs) and around (9 SNPs) 
the LEP gene. Out of the 20 SNPs within the gene, 18 were associated with 
the BMI (see Table 2) at a level of p<0.05, but merely in men. Only one SNP, 
rs2167270, has reached a p-value of 0.049 in women. The search for other 
studies dealing with one or more of the named SNPs has revealed positive 
hits for a couple of polymorphisms. However they are not mentioned here as 
they deal with cancer or spina bifida. Rs7799039 and rs2167270, in contrast, 
have been associated with various MetS features in numerous studies and 
therefore a couple of them are presented subsequently. 
 
One of those studies has been carried out by CONSTANTIN et al. (2010). 
They have analyzed 202 subjects (obese and non-obese) for linkage of 
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rs7799039 to obesity. In contrast to JIANG et al. (2004), the LEP 
polymorphism has shown no significant associations. FURUSAWA et al. 
(2010) have also analyzed if there is a connection between the same 
polymorphism and obesity. But the SNP has not been associated with neither 
BMI nor obesity. 
 
Studies dealing with insulin resistance have been found with the catchwords 
“leptin”, “polymorphism”, ”association” and “insulin resistance”/”T2D”. Most of 
them were excluded because they were dealing with the receptor instead but 
were included in the LEPR results chapter later on. The one study indeed 
dealing with LEP has been carried out by HAN et al. (2008). In 752 Korean 
women, rs28936687 and 4998A>C have been identified as marginally 
associated with T2D. Similar results were achieved when looking for 
associations of LEP with inflammation. Generally, all results were considering 
the LEPR gene polymorphisms and therefore were excluded in this part. 
 
The search for the catchwords “leptin”, “polymorphism”, ”association” and 
“lipid” has also revealed only few fitting results. The use of “HDL”, “LDL” or 
“lipoproteins” as substitutes for “lipid” did not change the outcome 
significantly. One of the studies that appeared was conducted by OKADA et 
al. (2010). They have performed a research looking for association of 
rs2167270, rs7799039, 188C>A, 633C>A and serum lipids in Japanese 
obese children. But none of the polymorphisms has shown any significant 
relationships.  
 
The search for polymorphisms that are causing changes in the leptin levels 
are usually variations from the LEPR gene and are therefore shown 
afterwards. The LEP gene was only mentioned by MA et al. (2009) but they 
have found no significant associations between LEP and plasma leptin levels 
when looking at them. Only rs28954369 and rs2060715, which is not located 
in LEP gene but in an intergenic region, came close to the level. 
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SNP Other name Authors Associated with 
rs10954174    SOBER et al. 2009 Diastolic BP 
rs13245201   MA et al. 2009 BP in post-menopausal women 
rs7799039 G2548A MA et al. 2009 BP in post-menopausal women 
    GANELHU et al. 2009 BP in obese women 
    BEN ALI et al. 2008 BP in obese men 
    JIANG et al. 2004 BMI in men 
    CONSTANTIN et al. 2010 No association with obesity 
    FURUSAWA et al. 2010 No association with obesity or BMI 
    OKADA et al. 2010 No association with serum lipids 
rs6467166   MA et al. BP in post-menopausal women 
    JIANG et al. 2004 BMI in men 
rs12536535   MA et al. BP in post-menopausal women 
    JIANG et al. 2004 BMI in men 
rs10244329    MA et al. BP in post-menopausal women 
    JIANG et al. 2004 BMI in men 
rs11763517   MA et al. BP in post-menopausal women 
rs28954369    MA et al. 2009 Tendency to accociation to leptin 
levels 
rs10249476   JIANG et al. 2004 BMI in men 
rs1349419   JIANG et al. 2004 BMI in men 
H1328083   JIANG et al. 2004 BMI in men 
rs12535708   JIANG et al. 2004 BMI in men 
rs11770725   JIANG et al. 2004 BMI in men 
rs12535747   JIANG et al. 2004 BMI in men 
rs13228377 G1387A JIANG et al. 2004 BMI in men 
rs2167270 A19G JIANG et al. 2004 BMI in men 
    OKADA et al. 2010 No association to serum lipids 
rs2278815   JIANG et al. 2004 BMI in men 
H1432616   JIANG et al. 2004 BMI in men 
H1432615   JIANG et al. 2004 BMI in men 
rs11763517   JIANG et al. 2004 BMI in men 
rs11760956   JIANG et al. 2004 BMI in men 
rs10954173   JIANG et al. 2004 BMI in men 
rs28936687   HAN et al. 2008 T2D 
  4998A>C HAN et al. 2008 T2D 
  1887C>A OKADA et al. 2010 No association with serum lipids 
  633C>A OKADA et al. 2010 No association with serum lipids 
Table 2: Overview of all mentioned LEP polymorphisms and their associations 
Polymorphisms that have an impact on the leptin level but are not located on 
the LEP or LEPR gene have also been reported. DO et al. (2008) have 
conducted a GWAS within the WTCCC considering 908 individuals who 
feature an association of rs17817449, which is located on the FTO gene, with 
plasma leptin levels at the p<0.05 level (p=0.036). Additional genes 
containing polymorphisms that have been associated with leptin levels and 
MetS features are located e.g. on the tumor necrosis factor α receptor gene 
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(TNF-α-R2) (A3 allele) [FERNANDEZ-REAL et al. 2000], on the β-3-
adrenergic receptor gene (Trp64Arg) [LIN et al.1999] or on the peroxisome 
proliferator-activated receptor gene (PPAR) (C/T exon 6) [MEIRHAGHE 
1998]. 
 
Genes that do not have an influence on leptin levels but an effect on MetS by 
modulating the leptin signalling pathways have also been included into the 
search. A gene that is thought to play a role in the regulation of body weight 
and fat through leptin is the SH2B gene. A study by JAMSHIDI et al. (2007) 
in 2455 white female twins in the UK (Twins United Kingdom) has revealed 
that the tagging SNP rs7498665, which represents 5 common SNPs in 
perfect LD (r2 = 1), has shown an association when it was linked to body fat 
and serum leptin levels (p-value = 0.04 in both). A further study has been 
carried out by OLIVIER et al. (2004). They have reported that 54281T>A on 
the PTPN1 (Protein-tyrosine phoshatase, non receptor type 1) is associated 
with hypertension (p=0.02).  
 
Obesity e.g. has been associatied to polymophisms on the SOCS3 gene by 
TALBERT et al. (2009). They have conducted a study in 1425 Hispanics 
investigating the associations of the SNPs in the SOCS3 gene, which is a 
leptin signalling inhibitor, with BMI, visceral adipose tissue and WC. 
Rs9914220 has been associated to all three features (p-values from 0.003 to 
0.017). JAK2 variants have been linked to body fat but also to insulin 
sensitivity and lipid profile. As explained in the leptin signalling subchapter, 
JAK2 is crucial for the functioning of leptin, which might explain the effects. 
Two polymorphisms located on it have been related to MetS features. 
Rs7849191 has been associated with body fat and WC (p=0.03 and 0.027) 
while rs3780378 to total cholesterol, LDL cholesterol and triglycerides 
(p=0.014, 0.012 and 0.023) [GE et al. 2008]. 
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SNP Other name  Gene Authors Associated with: 
rs17817449   FTO DO et al. 2008 Leptin levels 
  A3 allele TNFalphaR2 FERNANDEZ-REAL et 
al. 2000 
Leptin levels, insulin 
resistance 
  Trp64Arg Beta-3- adren. 
Recep. 
LIN et al. 1999 Leptin levels 
  C/T exon 6 PPAR MEIRHAGHE et al. 
1998 
Leptin levels 
rs7498665   SH2B JAMSHIDI et al. 2007 Body weight 
  54281T>A  PTPN1 OLIVIER et al. 2004 Hypertension 
rs9914220    SOCS3 TALBERT et al. 2009 BMI, visceral adipose tissue, 
WC 
rs7849191    JAK2 GE et al. 2008 Body fat and WC 
rs3780378    JAK2 GE et al. 2008 Total cholesterol, LDL 
cholesterol, triglycerides 
Table 3: Overview of all mentioned polymorphisms associated with leptin levels or MetS 
features not located on the LEP gene 
5.1.3. LEP - Discussion 
 
In general it can be said that polymorphisms on the LEP gene do not play a 
big role in the development of MetS, as the results are not as fruitful as 
expected. Only rs7799039 has shown some promising results. Associations 
with BP and BMI have been reported but then again these findings have 
been disproved by other studies. Reasons for these outcomes might be 
diverse.  
 
Most of these studies had not many subjects for investigation. Inclusion 
criteria e.g. for insulin resistance are often not mentioned. But it is also 
possible that variations in the LEP gene just do not play a role. It has been 
observed earlier that leptin levels are high in obese people leading to the 
conclusion that defects of function are due to the leptin receptor and not to a 
lack of leptin. Leptin deficiencies that lead to morbid obesity are very rare 
[FAROOQI and O`RAHILLY 2009] and cannot be accounted for general 
development of MetS. 
 
Outcomes showing that some polymorphisms are sex-specific indicate that 
endogenous hormones might be important, too. Testosterone and oestrogen 
might play a crucial role. These data are supported by MARTIN et al. (2002). 
They concluded that it is not only due to the different fat amounts in men and 
women but also due to the different expression of genes in the sexes. It has 
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been shown that testosterone plays a role in modulating leptin levels. A 
suppression results in an increase in leptin [ELBERS et al. 1997]. But 
whether the modulation effects of these hormones on leptin levels can 
explain the differences between prevalence of e.g. hypertension in men and 
women remains to be investigated. 
 
Another possibility of failure of detection might be due to underrepresentation 
of the SNPs on the arrays. With time these platforms contain more and more 
SNPs but maybe some important polymorphisms are still missing.  
 
It is also supposable that polymorphism on the LEP gene might be 
associated with LEPR SNPs and that only in combination they are causing 
MetS. 
5.2. LEPR 
5.2.1.  LEPR - GWAS results  
 
The search for significant LEPR results in GWAS revealed substantial hits. 
The Interrogator revealed 4 studies, which reached significant results under 
the needed criteria of 100.000 genotyped SNPs and a p-value of 5x10-5. 
These findings are summarized in Table 4 for easier overview. 
 
One of the studies has been conducted by SUN et al. (2010), aiming to 
discover if there are polymorphisms in the LEPR gene that function as 
determinants of the plasma soluble leptin receptor. They have analyzed 1504 
women from the Nurses‘ Health Study and detected 26 SNPs that are 
significantly associated with LEPRe (p-value < 5x10-8) all mapping to the 
LEPR gene. Additional 106 SNPs have been included because of analysis of 
imputed genotypes on autosomal chromosomes. Of the total 132 SNPs three 
SNPs remained associated with LEPRe at the 0.05 level: rs2767485 (p=9.1 x 
10-9), rs1751492 (p=0.0105), rs4655555 (p=0.0267). These results have 
been replicated in a sample of young males (n=875) residing in Cyprus. As 
full access to the study was not allowed, p-values of the replication study 
were not available. This is important to know as the GWAS interrogator 
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revealed rs1751492 as the only SNP reaching the GWAS significance level 
with a p-value of 6x10-13. Further search for the mentioned SNPs has 
revealed no more hits. 
 
The other three studies with significant results have shown associations with 
CRP levels, which points out the linkage of leptin and inflammation. RIDKER 
et al. (2008) have evaluated 336.108 SNPs in 6345 women from the 
Women‘s Genome Health Study. The initial group contained 4418 study 
participants and then promising results were replicated in a second group of 
1927 participants. 46 SNPs have been associated with CRP at a genome 
wide level of significance (p=5x10-8). Nine of these SNPs (rs1892534 p=6.5x 
10-21, rs2889195 p=2.78 x 10-20, rs2211651 p=3.10 x10-20, rs12753193 
p=3.27x10-17, rs2186245 p=1.27x10-13, rs12022410 p=7.47x10-13, rs7539471 
p=1.87x10-10, rs4291477 p=7.65x10-10 and rs4655537 p=3.28x10-9) are 
clustered in the LEPR gene. RIDKER et al. (2008) have also reported that 
1.6% of the CRP level variation has been due to the rs1892534 
polymorphism, which is also the only SNP mentioned in the GWAS 
interrogator. Additional search for the individual SNPs has revealed hits for 
rs1892534. These studies have not been included though because of dealing 
with irrelevant topics. The other polymorphisms showed either no results or 
again no results that were adequate. 
 
The second study has been conducted by ELLIOTT et al. (2009) with the aim 
to find genetic loci that are influencing CRP levels and are causing the risk of 
CHD. 17977 participants from five studies (LOLIPOP, NFBC, CoLaus, GEMS 
and DESIR) were analyzed and an additional 14747 LOLIPOP participants 
(not included in the initial GWAS) were used for the replication study. 
ELLIOTT et al. (2009) have found 160 SNPs in five different loci that have 
been associated with the CRP levels at a significance level of p<5x10-8. One 
of those SNPs was on the LEPR gene locus. This polymorphism, rs6700896, 
has been shown to be strongly associated with reduced CRP levels (p= 1.6x 
10-21) and increased CHD (coronary heart disease) risk. These have been 
completely new findings suggesting that CRP does not mediate CHD. 
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The third study and the last with significant results has been carried out by 
SABATTI et al. (2008). 329.091 SNPs were analyzed in 4763 individuals 
from the NFBC1966 for association in 9 metabolic traits (BMI, TG, HDL, LDL, 
glucose, insulin, CRP, systolic BP and diastolic BP). In the main analysis 21 
SNPs have shown an association with a p-value <5x10-7. Rs12753193, one 
of those SNPs, is located on LEPR and has been linked to C-reactive protein 
levels with a p-value of 3.76 x 10-7. 
 
GWAS that have been conducted but did not reach the significance level of 
5x10-5 and/or did not test 100.000 SNP as well as other types of studies have 
been looked for in PubMed. The catchwords “genome-wide association” and 
LEPR revealed, next to already above described studies, the study by 
SOBER et al. (2009) which was explained closer in the LEP GWAS results 
part. Next to LEP polymorphisms, this study group also analyzed 2 LEPR 
SNPs (rs10889553 and rs17097182). Although none of the p-values 
remained significant after the Bonferroni correction (p<0.05/2319, p=2.15x10-
5), the association between rs10889553 and systolic BP (p=4.5x10-5) was 
close to the cut-off point. The search for other studies concerning LEPR 
polymorphisms and hypertension revealed no further GWAS hits but results 
from studies with other design. 
 
SNP Other name Authors Associatied with: 
rs2767485    SUN et al. 2010 Plasma soluble leptin receptor 
rs1751492    SUN et al. 2010 Plasma soluble leptin receptor 
rs4655555   SUN et al. 2010 Plasma soluble leptin receptor 
rs1892534    RIDKER et al. 2008 CRP levels 
rs2889195    RIDKER et al. 2008 CRP levels 
rs2211651    RIDKER et al. 2008 CRP levels 
rs12753193    RIDKER et al. 2008 CRP levels 
    SABATTI et al. 2008 CRP levels 
rs2186245    RIDKER et al. 2008 CRP levels 
rs12022410    RIDKER et al. 2008 CRP levels 
rs7539471    RIDKER et al. 2008 CRP levels 
rs4291477    RIDKER et al. 2008 CRP levels 
rs4655537    RIDKER et al. 2008 CRP levels 
rs6700896   ELLIOTT et al. 2009 
 
reduced CRP levels, 
increased CHD risk 
rs10889553    SOBER et al. 2009 systolic BP 
rs17097182   SOBER et al. 2009 systolic BP 
Table 4: Overview of all mentioned LEPR polymoprhisms from GWAS and their associations 
	   43	  
5.2.2. LEPR - Further results 
 
To continue with the significant CRP results, like those from the GWAS, a 
study by ZHANG et al. (2007) is presented. This research group has namely 
identified rs3790432 and rs1805096 in 630 Caucasians as being associated 
with fibrinogen and CRP – both markers for inflammation. Further results for 
these SNPs were only interesting for rs1805096. An appearing study, by 
PHILLIPS et al. (2010), is mentioned in the dyslipidemia part also, as it 
additionally reports rs8179183, too. 
 
It has to be emphasized that there are four common polymorphisms on the 
LEPR gene - rs1137100 (Lys109Arg), rs1137101 (Gln223Arg), rs790419 
(Ser343Ser) and rs8179183 (Lys656Asn) - which have been in the focus of 
researchers. They are mentioned here because they are used in most of the 
studies like in the one that has been conducted by LINSHUAN et al. (2008). 
They have investigated the association of rs1137101 with hypertension in 
patients with IGT in 572 subjects (252 with normal glucose tolerance, 320 
with IGT). The results have shown that the polymorphism is associated with 
hypertension but only in IGT male patients. Similar results have been shown 
by RUOWANG et al. (2008), who also demonstrated that rs1137101 might be 
the causation of hypertension in obese patients. 
 
Studies concerning associations of LEPR with obesity have been found 
through the catchwords “leptin receptor”, “obesity”, “polymorphism” and 
“association”. MARTI et al. (2009) have carried out one of the detected 
studies. In their case-control study with obese subjects (n=159) and normal 
weight controls (n=154) they have genotyped the four common 
polymorphisms of the LERP gene (rs1137100, rs1137101, rs790419 and 
rs8179183). No significant case-control differences and no associations 
between the SNPs and obesity or serum leptin levels have been found. 
These findings are supported by CONSTANTIN et al. (2010) and their study, 
already mentioned in the LEP results. They have reported that in their 202 
Romanian subjects rs1137101 might also not be considered as a genetic risk 
factor for obesity. PYRZAK et al. (2009) have shown also that in their case-
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control study there is no association of LEPR rs1137101 polymorphism with 
leptin, obesity or metabolic disturbances. 
 
A study by FURUSAWA et al. (2010), in contrast, has shown associations 
between the polymorphisms and obesity. Their research group has carried 
out a study in 809 individuals from the Pacific Islands (Micronesian, 
Polynesian and Melanesian populations) where they were, among others, 
looking for associations of known LEPR polymorphisms (rs1137100 and 
rs1137101) with obesity. Their results have shown that carriers of rs1137101 
had significantly higher body weight (p=0.0009) and BMI (p= 0.0022) as well 
as that they were more obese (p=0.0222). These findings are supported by 
BEN ALI et al. (2009). In their case-control study with 391 obese and 302 
normal weight subjects they have pointed out that rs1137101 influences 
plasma leptin levels and is also associated with BMI in obese patients. 
DUARTE et al. (2007) have also reported an association of LEPR and body 
weight regulation. Their case-control study has revealed that rs1137101 is 
related to BMI increase. GALLICHIO et al. (2009) support these findings by 
showing that rs1045895 and rs1137101 are associated with BMI change.  
 
It has already been mentioned in this thesis that the function of leptin does 
not depend on the amount of leptin, as obese people have a high level of 
leptin, but on the functioning of the leptin receptor. Polymorphisms in the 
LEPR gene that might have an effect on leptin levels have also been 
searched for. RIESTRA et al. (2010) have reported that rs1137101 is 
significantly associated with serum leptin levels (p=0.016) but only in girls. 
RAGIN et al. (2009) support these findings in their study, with 1418 healthy 
subjects from various ethnic groups. They have suggested rs1137101 to be 
associated with circulating plasma leptin levels but only in postmenopausal 
Caucasian women. POPRUK et al. (2008) have also shown an effect of a 
polymorphism on leptin levels in Thai children, although not from rs1137101 
but from rs8179183. They have reported an association of rs8179183 with 
cholesterol and LDL levels. 
 
Further studies concerning polymorphisms and their effects on lipids were 
found with the catchwords “leptin receptor”, “polymorphism”, “association” 
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and “lipid”. OKADA et al. (2010), already mentioned above, have conducted 
a study where they have analyzed 136 obese Japanese children looking for 
associations between LEPR polymorphisms and serum lipids. They have 
reported that LEPR gene SNPs might partly contribute to the profiles as 
rs1137100 and rs790419 showed significant effects but rs1137101 e.g. did 
not. VAN DER VLEUTEN et al. (2006) have carried out a study where they 
looked at 644 subjects of which 158 had hyperlipidemia. As a result, 
rs1137101 has been pointed out to have an association with HDL-C. 
PHILLIPS et al. (2009), already mentioned above, have investigated the 
relationships among LEPR polymorphisms and various MetS features. 
Subjects with rs3790432 had higher risk for developing MetS and this 
polymorphism has shown associations with plasma fatty acids. 
 
Studies dealing with insulin resistance have been found by combinations of 
the catchwords “insulin”, “polymorphism”, “association” and “leptin receptor”. 
DE LUIS et al. (2008) have analyzed 233 obese non-diabetic subjects and 
reported rs8179183 to be associated with higher levels of insulin and leptin 
but only in males. SALOPURO et al. (2005) have conducted a study where 
they have evaluated the association between LEPR polymorphisms and 
diabetes risk as well as bodyweight in 507 individuals with IGT. Rs1137100 
and rs1137101 have been linked to higher risk for T2D. Both of these studies 
support the first findings by CHIU et al. (2004). They have namely reported 
an association of rs1137101 and insulin sensitivity as well as glucose 
clearance. 
 
Associations between the rs1137101 polymorphism of the leptin receptor and 
the MetS in general was reported by GOTTLIEB et al. (2009) in free-living 
elderly in Brazil. 
 
Other genes that might influence the leptin receptor have only been reported 
by SANTANIEMI et al. (2004). In their study they showed two polymorphisms 
of tyrosine phosphatase 1B interact with LEPR rs1137101, which results in 
influencing the BMI and explaining 3% of its variation. 
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SNP Other name Authors Associated with: 
rs1137100  Lys109Arg MARTI et al 2009 No association with obesity or 
leptin levels 
    FURUSAWA et al. 2010 No association with obesity 
    OKADA et al. 2010 Lipid profiles 
    SALOPURO et al. 2005 T2D 
rs1137101  Gln223Arg LINSHUAN et al. 2008 Hypertension in male IGT 
patients 
    RUOWANG et al. 2008 Hypertension in obese 
patients 
    MARTI et al. 2009 No association with obesity or 
leptin levels 
    CONSTANTINI et al. 2010 No association with obesity 
    PYRZAK et al. 2009 No association with obesity 
    FURUSAWA et al. 2010 Higher body weight 
    BEN ALI 2009 Higher body weight and leptin 
levels 
    DUARTE et al. 2007 BMI increase 
    GALLICHIO et al. 2009 BMI increase 
    RIESTRA et al. 2010 Leptin levels in girls 
    RAGIN et al. 2009 Leptin levels in 
postmenopausal women 
    OKADA et al. 2010 no association with lipid 
profiles 
    VAN DER VLEUTEN et al. 
2006 
HDL- cholesterol 
    SALOPURO et al. 2005 T2D 
    CHIU et al. 2004 Insulin sensitivity and glucose 
clearance 
    GOTTLIEB et al. 2009 Metabolic Syndrome  
rs790419  Ser343Ser MARTI et al. 2009 No association with obesity or 
leptin levels 
    OKADA et al. 2010 Lipid profiles 
        
rs8179183  Lys656Asn MARTI et al. 2009 No association with obesity or 
leptin levels 
    POPRUK et al. 2008 Leptin levels 
    POPRUK et al. 2008 Cholesterol and LDL levels 
    DE LUIS et al. 2008 
 
PHILLIPS et al. 2010 
Higher linsulin and leptin 
levels in males 
Plasma fatty acids, MetS 
rs3790432    ZHANG et al. 2007 CRP levels 
rs1805096    ZHANG et al. 2007 
PHILLIPS et al. 2010 
CRP levels 
Plasma fatty acids, MetS 
rs1045895    GALLICHIO et al. 2009 BMI increase 
Table 5: Overview of all mentionend LEPR polymorphisms and their associations 
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5.2.3.  LEPR - Discussion 
 
As with the LEP results the findings are varying but it has to be said that the 
outcomes are more promising. Nevertheless, considering the results of the 
individual SNPs it remains hard to say if LEPR really plays a role in the 
development of the MetS. Rs1137101 has been the most investigated and 
the most discussed LEPR polymorphism. It has been linked to hypertension, 
obesity, leptin levels, lipid profiles but most of these associations have been 
refuted again. The most promising results refer the polymorphisms 
influencing CRP levels, which is the correlation of LEPR and inflammation. 
Therefore it might be important to add CRP as an additional factor to MetS 
definition. 
 
The reason for these unsatisfying outcomes might be the same as for LEP. 
Again, the inclusion criteria of patients can be questioned as well as the 
amount of tested subjects. Not many GWAS are available and studies with 
other study designs just might not have enough people to have significant 
outcomes without false positive results. It can also occur that the 
polymorphisms on the arrays are just not representing the important 
polymorphisms leading to the fact that those cannot be found. If there are 
some results shown it is also a question which p-values are necessary to 
consider those significant. Not every study is corrected for the tested SNPs 
and some just take given significance levels and apply them to their studies. 
This might include many false-positive results but also exclude promising 
candidates. 
 
Influences of other genes have not been reported yet. Above a possible 
interaction of LEPR and TP1B is pointed out. A further possibility would also 
be that not the LEP and LEPR polymorphisms are causing e.g. obesity but 
rather the other way round. Unhealthy eating habits and obesity could 
influence the expression of genes and the signalling pathways leading to 
numerous small dysfunctions that affect the communication of cells and in 
the end result in a vicious cycle that ends in a cluster of diseases like MetS. 
Leptin and its corresponding receptor play a major role in cell communication 
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when people are “normal” but probably are constricted through westernized 
lifestyle. In that case genes would play no role at all.  
 
An interesting study has been published by DEMOOR et al. (2009). This 
GWAS has analyzed the associations of LEPR polymorphisms and leisure 
time behaviour like exercise participation for example. Rs12405556 reached 
a p-value of 9.7 × 10-4. This means that if there are genes that influence our 
urge to move they could be the ones that are indirectly causing the MetS. But 
it is more likely that they have only a small size effect. 
5.3. ADIPOQ 
5.3.1. ADIPOQ - GWAS results 
 
The search for GWAS results in the HuGE Navigator for the ADIPOQ gene 
revealed three studies presenting four significant SNPs, all of them being 
associated with adiponectin levels.  
 
HEID et al. (2010) have reported one of the significant polymorphisms. They 
have conducted a study with the aim to find SNPs associated with plasma 
adiponectin levels, which might explain the difference between men and 
women. 4659 subjects (w=2562, m=2097) that derived from ERF, KORA and 
MICROS have been tested in the first stage for 2.585.854 SNPs. 40 of these 
were considered to be interesting because they had combined p-values 
<1x10-4 and a minor allele frequency (MAF) greater than 5%. Additionally, 73 
SNPs, associated with MetS parameters before, have been selected and 
studied for their association with plasma adiponectin. The primarily selected 
40 SNPs have been checked in stage 2 by carrying out a replication study 
based on 7 cohort studies (CoLaus, Framingham, GEMS, ALSPAC, TWINS 
UK, InChianti and BLSA). Only one SNP has reached genome-wide 
significance, namely rs17366568 with a combined p-value of 4.3x10-24, which 
has been consistent in women (p=8.7x10-17) and men (2.5x10-11). Although 
the p-values were different in the sexes the differences in plasma adiponectin 
levels could not be explained by the top SNP as it revealed a p-value of 0.62 
suggesting that the differences seem to be more influenced by sex hormones 
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than by the gene itself. It is interesting to know that rs17366568 is completely 
independent of all the other SNPs in the ADIPOQ region. Many SNPs that 
are located in the same region have a weak r2 even if they are located on the 
same LD block. The percentage of plasma variance ranged from 3.9% to 
6.7% depending on whether only the rs17366568 has been considered or all 
the SNPs with MAF >5% within the LD blocks have been included. An 
association with any of the additionally included 73 polymorphisms did not 
reveal any convincing results with plasma adiponectin levels. Further 
outcomes for this SNP are mentioned later on. 
 
The second study, which has revealed significant results, has been carried 
out by LING et al. (2009). Like HEID et al. (2009) they also aimed to identify 
genes influencing adiponectin levels. The GEMS study has included 1845 
subjects (997 cases, 989 controls), which have been tested for the desired 
associations. Out of 10 strongly associated SNPs, five were located on 
genes. Three of them, rs6773957 (p=4.78x10-8), rs3774261 (p=5.15x10-8) 
and rs17366568 (p=3.70x10-6) were directly in the ADIPOQ gene. 
Rs3774261 and rs6773957 have remained associated in controls (p=0.004 
and p=0.003) but only rs6773957 was mentioned in the Interrogator. These 
two SNPs revealed to be highly correlated (r2=0.98). Rs3774261 accounted 
for 1.2% of the total variance in plasma adiponectin level in the pooled 
sample of cases and controls. Associations of these two ADIPOQ SNPs with 
other MetS parameters have not achieved any statistical significance (all 
p>0.001). Rs6773957 is additionally mentioned in the further results for 
LEPR polymorphisms. 
 
The third study, which has reported two significant results in the GWAS 
Interrogator has been conducted by RICHARDS et al. (2009). They meta-
analyzed three GWAS (TwinsUK, GEMS, CoLaus) initially containing 8531 
participants for circulating adiponectin levels. The most strongly associated 
SNPs (p<11x10-4, n=250) have been chosen and tested in five additional 
cohorts (BLSA, EPIC-Norfolk, Framingham, INCHIANTI, ALSPAC) containing 
6202 subjects in total. 5 SNPs have achieved genome-wide significance (p< 
5x10-8) and have been tested for their association with MetS and its traits in 
further independent cohorts. Associations with T2D have been tested in the 
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DIAGRAM consortium (10.128 subjects), those with insulin resistance in 
MAGIC (24.188 people), those with CHD in a consortium of 8 cohorts and 
those with BMI in the GIANT cohort (32.527 subjects). In total, 4 SNPs have 
shown genome-wide significance: rs6444175 (p=1.2x10-21), rs266717, 
rs1426810 (p=2.2x10-18), rs1648707 (p=3.0x10-12). The most strongly 
associated SNP has been rs266717 with a p-value of 9.2x10-19. The findings 
have been consistant through all stages. Only rs6444175 has demonstrated 
heterogeneity, and therefore, although the p-value is better than in rs266717, 
it is not the most strongly associated polymorphism. Interestingly the GWAS 
HuGE Navigator only mentions rs266717 and rs1648707 to have reached 
significance level. These four reported polymorphisms have also been tested 
for MetS traits but none of the SNPs in the ADIPOQ locus has shown a 
significant relationship to T2D or CHD although rs1648707 has had some 
positive results (CHD p-value=0.04 and T2D p-value=0.046). Rs1648707 is 
in moderate linkage disequilibrium with rs266729 (r2=0.74), which has been 
associated with adiponectin levels earlier on [MENZAGHI et al. 2007], but not 
with T2D. Further results are only added for rs6444175 later on. 
 
Further GWAS hits have been searched for with combinations of catchwords 
in PubMed, without any results. 
 
SNP Other name Authors Associated with: 
rs17366568    HEID et al. 2010 Adiponectin levels 
rs3774261    LING et al. 2009 Adiponectin levels 
rs6773957    LING et al. 2009 Adiponectin levels 
rs6444175    RICHARDS et al. 2009 Adiponectin levels, no 
association to T2D or CHD 
rs1426810    RICHARDS et al. 2009 Adiponectin levels, no 
association to T2D or CHD 
rs1648707    RICHARDS et al. 2009 Adiponectin levels, possible 
association with T2D and 
CHD 
rs266717    RICHARDS et al. 2009 Adiponectin levels, no 
association to T2D or CHD 
Table 6: Overview of all mentioned ADIPOQ polymorphisms in GWAS and their associations 
5.3.2. ADIPOQ - Further results 
 
Like in the chapters dealing with LEP and LEPR, further study designs and 
their outcomes have been included into ADIPOQ results due to unavailable, 
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missing or insufficient GWAS achievements. Generally it can be said that, 
like for LEPR, common SNPs have been reported, namely rs17300539, 
rs266729, rs2241766 and rs1501299 [CHIODINI et al. 2010], which were 
investigated more closely. Most of the studies were dealing with obesity, 
insulin resistance and adiponectin levels. Therefore results for hypertension, 
dyslipidemia or inflammation are scarce or not available, showing that that 
those associations have not been analyzed until now. 
 
To continue with polymorphisms influencing adiponectin levels a study by 
HENNEMAN et al. (2010) is presented. They have conducted an 
investigation where they have evaluated the associations of MetS and its 
features with 10 earlier reported ADIPOQ SNPs. Their family-based 
population (ERF) has included 1,258 women and 967 men, which have 
revealed significant associations of plasma adiponectin with the ADIPOQ 
variants rs17300539 (p=9.3x10-5) and rs182052 (p=3.0x10-4). For the first 
one (rs17300539) an association with plasma insulin is reported additionally. 
Similar findings have been reported by HIVERT et al. (2008) before. In their 
study 2.543 individuals from FOS have been analyzed and rs17300539 and 
rs822387 have been reported to be associated with adiponectin levels 
(p=0.0005 and p=0.001). Furthermore, these two polymorphisms have been 
shown to be in strong LD (r2=0.8). Additionally rs6773957 and rs6444175, 
from an untranslated region (3`UTR), were associated with adiponectin 
levels, too (p=0.002 and p=0.04). The latter SNP and rs1501299 have 
demonstrated a state of strong linkage disequilibrium (r2=0.92) but 
rs1501299 has lacked to show significant association with adiponectin levels 
(p=0.1). Linkage to MetS was only shown by a nonsynonymous SNP 
(rs17366743), which has been associated with diabetes incidence (p=0.004). 
 
A few opposing results have been shown by HEID et al. (2006) and 
MENZAGHI et al. (2007). The first ones also reported rs822387 to be 
associated with higher adiponectin and in high LD with rs17300539. But in 
contrast to HIVERT et al. (2008) they reported that no association of 
rs17366743 and MetS has been observed. MENZAGHI et al. (2007) have 
also declared rs17300539 to have an effect on adiponecintaemia. 
Furthermore rs1501299 has been shown to have an effect on adiponectin 
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levels, insulin resistance and CAD (coronary aretery disease). Additionally 
rs1501299 has been reported to be in LD with a 3´UTR variant. Rs266729 
has been identified to be associated with higher adiponectin levels. 
 
VIMALESWARAN et al. (2008) have analyzed 2.000 people affected with 
T2D and 2.000 with normal glucose tolerance with the aim to find variants 
that contribute to the development of T2D in Asian Indians. They found a 
polymorphism, rs17846866, contributing to development of T2D, obesity and 
hypoadiponectinemia. 
 
Searching for results concerning adiponectin polymorphisms and obesity, 
similar to the chapters before, the catchwords “adiponectin”, “polymorphism”, 
“association” and “obesity” have been used. Looking through various studies 
especially two SNPs have been in the focus of investigation - rs2241766 and 
rs1501299. The diverse results of those are explained subsequently. It has 
also to be mentioned that generally these studies have dealt with insulin 
resistance, too. Therefore both features of MetS, obesity and insulin 
resistance, are analyzed and presented simultaneously. 
 
YU et al. (2010) wanted to know if there is an association of rs2241766 and 
adolescent obesity. For that, 47 obese and 50 subjects with normal weight 
have been analyzed showing no association. These findings are supported 
by the study of LEE et al. (2010), who have analyzed the associations of 
rs2241766 and rs1501299 with obesity-related phenotypes in 1260 twin pairs 
but they did not find any bond. An association of rs2241766 with IR, in 
contrast, has been shown to exist [YU et al. 2010]. These data have been 
refuted by CHIODINI et al. (2010). In their case-control study with 2008 
Italians, the SNPs rs17300539, rs266729 and rs2241766 had no significant 
associations with T2D or myocardial infarction unlike rs1501299 
polymorphism mentioned above, which has been linked to decreased risk of 
myocardial infarction (p=0.01).  
 
Similar results to those of CHIODINI et al. (2010) have been reported before 
by JANG et al. (2006). They aimed to determine whether polymorphisms of 
the ADIPOQ gene contribute to IR and CVD in non-obese and non-
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Korean men and have reported that rs1501299 rather than rs2241766 is 
associated with several components of MetS and CVD risk, including IR, 
triglyceride concentration, and low-density lipoprotein particle size. 
PANAGOPOULOU et al. (2009) have confirmed these findings by analyzing 
48 obese children from Greece for their association of rs2241766 and 
rs1501299 with IR. Rs2241766 has not been associated with decreased risk 
for IR but rs1501299 has been reported to possibly be protective against IR. 
MOHAMMADZADEH and ZARGHAMI (2009) confirm these results by 
reporting that in their study rather rs2241766 than rs1501299 has been 
associated with risk in T2D in obese individuals. 
 
The search for studies dealing with hypertension or blood pressure revealed 
only a few results. Again a combination of catchwords (“adiponectin”, 
“polymorphism”, “association” and “hypertension”/”blood pressure”) has been 
used to find these. ANTONOPOULOS et al. (2009) have conducted a study 
to show if the rs2241766 polymorphism is associated with lower risk of 
arterial hypertension and decreased CVD risk. They have been able to point 
out that the SNP has an effect on adiponectin expression but only in healthy 
individuals, suggesting that higher adiponectin levels might prevent the 
appearance of CAD in healthy people but as soon as they are diseased the 
effect disappears. 
 
IWASHIMA et al. (2004) have investigated the associations of I164T and 
rs1501299. Whereas the latter has not been associated with adiponectin 
concentrations or hypertension the first one showed a lowering effect on 
adiponectin levels and was associated with appearance of hypertension. In 
the study by RONCONI et al. (2010) previous results for the two SNPs were 
approved. Rs2241766 has been shown to have a protective role, like 
reported by ANTONOPOULOS et al (2009), while rs1501299 appeared to 
have a worsening effect or no effect at all. 
 
Studies dealing with polymorphisms of adiponectin and their associations 
with dyslipidemia have been identified by using combinations of the 
catchwords “adiponectin”, “polymorphism”, “association” and “HDL” or “LDL”. 
BERTHIER et al. (2005) have examined the associations of adiponectin 
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polymorphisms and lipoprotein levels. Their data showed that carriers of 
rs1501299 had higher LDL and lower HDL levels but subjects with rs2241766 
had higher plasma adiponectin. These results have been supported by the 
findings of JANG et al. (2005) and JOHANSSON et al. (2009). The first ones 
have reported an association of rs1501299 with lower plasma adiponectin 
and significantly higher concentrations of LDL and triacylglycerol but no effect 
of rs2241766. The latter group has shown again a linkage of rs1501299 with 
LDL cholesterol. 
 
Although adiponectin and inflammation have been linked to each other, no 
polymorphisms have been investigated and reported until now. 
 
Influence on the adiponectin levels, not due to the ADIPOQ locus itself have 
been reported recently. RICHARDS et al. (2009) have identified a novel 
intronic SNP, rs4311394, which is located in the ARL15 (ADP-ribosylation 
factor like 15) gene. The polymorphism has been associated with decreased 
adiponectin levels (p=2.9x10-8) and linked to CHD (various cohorts, n= 
22421, p-value= 8.5x10-6), to an increased risk of T2D (DIAGRAM 
consortium, 10128 individuals, p=3.2x10-3) as well as to increased fasting 
insulin (MAGIC consortium, 24614 subjects, 2.3x10-3). The GIANT 
consortium has demonstrated a moderate but non-significant association with 
BMI (p=0.016).  
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SNP Other name Authors Associated with: 
rs17300539  11391G>A HENNEMAN et al. 2010 Adiponectin levels, plasma insulin 
    HIVERT et al. 2008 Adiponectin levels 
    HEID et al. 2006 No associations wit MetS 
    MENZAGHI et al. 2007 Adiponectinaemia 
    CHIODINI et al. 2010 No association with T2D or myocaridal 
infarction 
rs266729  11377C>G MENZAGHI et al. 2007 Adiponectin levels 
    CHIODINI et al. 2010 No association with T2D or myocaridal 
infarction 
rs2241766  45T>G YU et al. 2010 no association with obesity but with IR 
    LEE et al. 2010 no association with obesity 
    CHIODINI et al. 2010 No association with T2D or myocaridal 
infarction 
    JANG et al. 2006 Suggested association with IR, TG 
concentration, LDL size 
    PANGOPOULOU et al. 
2006 
No associaiton with decreased risk of IR 
    MOHAMMADZADEH and 
ZARGHAMI 2009 
increased risk of T2D 
    ANTONOPOULOS et al. 
2009 
Decreased cardiovascular risk 
    RONCONI et al. 2010 protection of hypertension 
    BERTHIER et al. 2005 Adiponectin levels 
    JANG et al. 2005 no asociation with adiponectin levels 
rs1501299  
 
276G>T LEE et al. 2010 no association with obesity 
   CHIODINI et al. 2010 Decreased risk of myocardial infarction 
   JANG et al. 2006 IR, TG concentration, LDL size 
   PANGOPOULOU et al. 
2006 
Protection against IR 
   MOHAMMADZADEH and 
ZARGHAMI 2009 
suggested risk of T2D 
   IWASHIMA et al. 2004 No association with adiponectin levels or 
hypertension 
   RONCONI et al. 2010 No association with adiponectin levels or 
hypertension 
   BERTHIER et al. 2005 Lipoprotein levels 
   JANG et al. 2005 Lower Adiponectin levels, high LDL level 
   JOHANSSON et al. 2009 LDL cholesterol 
   HIVERT et al. 2008 No associations with adiponectin levels 
   MENZAGHI et al. 2007 Adiponectin levels, insulin resistance, CAD 
rs182052    HENNEMAN et al. 2010 Adiponectin levels 
rs822387    HIVERT et al. 2008 Adiponectin levels 
    HEID et al. 2006 Adiponectin levels 
rs6773957    HIVERT et al. 2008 Adiponectin levels 
rs6444175   HIVERT et al. 2008 Adiponectin levels 
rs17366743   HIVERT et al. 2008 Diabetes 
    HEID et al. 2006 No associations wit MetS 
rs17846866   VIMALESWARAN et al. 
2008 
T2D, obesity, hypoadiponectinaemia 
  I64T IWASHIMA et al. 2004 Low adiponectin levels and hypertension 
Table 7: Overview of all mentioned ADIPOQ polymorphisms and their associations 
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5.3.3. ADIPOQ - Discussion  
 
So far adiponectin has been the most promising object of investigation as a 
lot of positive finding have been achieved. Especially the search for SNPs 
associated with adiponectin levels has been fruitful, as many results have 
been reported. Polymorphisms concerning MetS or any of its features 
however gave more inconsistent results. Rs2241766 has been reported to be 
associated with IR but also as not having any associations with T2D. For 
rs1501299 similar results have been achieved so protection against IR was 
suggested as was a higher risk to get T2D. Therefore, also for ADIPOQ, the 
question of how big its influence in the development of MetS is and if there 
actually is one at all, remains. 
 
Adiponectin has been shown to be negatively regulated in obesity, meaning 
that the more obese a person is the lower the adiponectin levels are. In 
contrast to leptin, a lack of adiponectin is associated with features of MetS. 
HEID et al. (2010) have shown that rs17366568 alone is accountable for 4% 
of the adiponectin level variance. Including other SNPs on the same LD block 
the influence has been up to 7%. Therefore people possessing one or all of 
these SNPs might be more protected from developing MetS than the ones 
without them. Nevertheless, the effect could not be proved as most of the 
studies revealed no association of MetS with that SNP. It has also been 
surprising that none of the 73 SNPs, which were additionally tested by 
HENNEMAN et al. (2010), did reveal any convincing associations although 
they have been reported to have a strong link to MetS. 
 
Next to the difficulties of study design and statistics that have already been 
mentioned in the LEP and/or LEPR results discussion, it is also possible that 
other genes have an influence on adiponectin as well and if so, the question 
arises how they influence it. For ARL15 it is still unclear how it interacts with 
adiponectin to influence the disease risk. But it might be a connection 
between insulin and adiponectin, where adiponectin acts through an insulin 
dependant pathway, which involves but does not depend entirely upon 
adiponectin [RICHARDS et al. 2009] 
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5.4. ADIPOR1, ADIPOR2 and CDH13 
5.4.1. ADIPOR1, ADIPOR2 and CDH13 - GWAS results 
 
The search for significant results in the HuGE Navigator GWAS Interrogator 
has revealed no significant hits for ADIPOR1 or ADIPOR2. The search for 
polymorphisms in CDH13, the gene encoding one of the three receptors, 
revealed two studies dealing with MetS with significant results.  
 
LEVY et al. (2007) conducted a study with the participants of the 
Framingham Heart Study analyzing 70.987 SNPs for their association with 
hypertension. Among the other genes found to be associated with 
hypertension they also identified rs3096277, a polymorphism on the CDH13 
gene, to be significantly linked to systolic and diastolic BP (p= 1x10-9). 
 
Similar findings, but with another SNPs, were achieved by ORG et al. (2009). 
They tested 1644 participants of the KORA S3 study and their associations of 
395.912 SNPs with SBP, DBP and hypertension. The initial results have 
been replicated in KORA S4 as well as HYPEST. Among the significant 
results was rs11646213, a variation on the CDH13 gene, showing 
associations with DBP (p=5.55x10-5), SBP (p=0.007) and hypertension 
(p=5.3x10-8).  
 
SNP Other name Authors Associated with: 
rs3096277   LEVY et al. 2007 Systolic and diastolic BP 
rs11646213    ORG et al. 2009 Diastolic BP and hypertension 
Table 8: Overview of all CDH13 polymorphisms and their associations 
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5.4.2. ADIPOR1, ADIPOR2 and CDH13 - Further results 
 
To give an overview what is known about ADIPOR1, ADIPOR2 and CDH13 
polymorphisms beyond the GWAS results also a PubMed search was 
conducted. Combinations of catchwords (“adiponectin receptor”, “adipor” or 
“CDH13” together with “polymorphism”, “association” and/or the MetS trait) 
was used to find the appropriate studies. Generally it can be said that 
primarily associations of ADIPOR1/ADIPOR2 with insulin resistance have 
been reported.  
 
RASMUSSEN-TORVIK et al. (2009) have reported various SNPs being 
associated with insulin sensitivity but dependant on ethnicity. Rs7539543 on 
the ADIPOR1 gene, for example, has been significant only in Whites. 
Rs1342387 from ADIPOR1 has also been significant but then again only in 
African-Americans. The SNP on the ADIPOR2 gene rs12826079 has shown 
a p-value of <0.05 but again only in Whites. A further study concerning 
insulin sensitivity has been conducted by RUCHAT et al. (2008). They have 
analyzed 100G>T and 3882T>C from the ADIPOR1 and 35361A>G and -
1352G>A from the ADIPOR2 gene and their associations with adiponectin 
plasma levels, indicators of glucose tolerance, insulin sensitivity (IS) and 
insulin secretion. Only the 3882T>C SNP on ADIPOR1 has been associated 
with fasting glucose (p=0.03), the homeostasis model assessment for insulin 
resistance (p=0.04) and an index of insulin secretion (P30/G30, p=0.02). No 
evidence of association has been found with plasma adiponectin levels. 
 
 
The study by POTAPOV et al. (2008) has shown three SNPs of which two 
(rs11061971 and rs16928751), both located in the ADIPOR2 gene, have 
been associated with higher risk of diabetes. The third SNP, rs22753738, 
from the ADIPOR1 gene has not shown any associations. KIM et al. (2009) 
have selected 7 SNPs from ADIPOR1 and 4 SNPs from ADIPOR2 and 
looked for their associations with T2D. None of the SNPs has shown any 
linkage. However rs75172865 from ADIPOR1 has been associated with 
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lower insulin resistance. 63442G and rs1044471 from the ADIPOR2 have 
been linked to lower waist circumference.  
 
Studies concerning dyslipidemia have been found when using the general 
catchwords in combination with “lipid”, “HDL”, “LDL” or “lipoprotein”. BROEDL 
et al. 2006 have been looking for association of ADIPO2 variants with 
triglyceride levels. They have found 795G/A, 870C/A and 963C/T to be in 
perfect linkage disequilibrium (r2=1) and additionally that they are associated 
with higher plasma adiponectin levels and decreased fasting triglyceride, 
VLDL-triglyceride and VLDL-cholesterol level. No association, however, has 
been observed between the AdipoR2 SNP cluster and glucose metabolism. 
FERGUSON et al. (2010) have conducted a study where they wanted to see 
if there are associations between SNPs on the ADIPOR1/ ADIPOR2 gene 
and plasma fatty composition. In their study only rs10920533 has been linked 
to levels of plasma saturated fatty acids. HALVATSIOTIS et al. (2010) have 
investigated the association of ADIPOR2 and CAD with the result that 
rs767870 possibly affects ADIPOR2 levels and consequently indirectly 
influences the development of CAD. KOTRONEN et al. (2009) have reported 
that rs767870 is associated with fat accumulation in the liver. 
 
LING et al. (2009) have also checked ADIPOR1 and ADIPOR2 SNPs in their 
study, which was described in more detail above, and their association to 
adiponectin levels. But they have not been able to demonstrate any relation. 
Their search for association with the third adiponectin receptor, T-cadherin, 
was more fruitful. They found a SNP that is located within CDH13, 
rs7195409, which has been associated with adiponectin levels (p=2.0x10-5). 
Generally, next to the GWAS results, this was the only study dealing with 
CDH13 and MetS. 
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SNP Other name Authors Associated with: 
ADIPOR1     
rs7539543  
   
RASMUSSEN-TORVIK 
et al. 2009 
Insulin sensitivity in Whites 
 
rs1342387 
    
RASMUSSEN-TORVIK 
et al. 2009 
Insulinsensitivity in African-Americans 
 
rs22753738 
   
POTAPOV et al. 2008 
 
No association of higher risk with diabetes  
 
rs75172865    KIM et al. 2009 Lower insulin resistance 
  100G>T  RUCHAT et al. 2008 No associations with insulin sensitivity 
  3882T>C  RUCHAT et al. 2008 Fasting glucose, insulin sensitivity 
ADIPOR2     
rs12826079 
    
RASMUSSEN-TORVIK 
et al. 2009 
Insulin sensitivity in Whites 
 
rs11061971    POTAPOV et al. 2008 Higher risk of diabetes 
rs16928751 
 
 
 
795G>A 
 
 
 
POTAPOV et al. 2008 
BROEDL et al. 2006 
 
 
Higher risk of diabetes 
Higher plasma adiponectin, lower fasting TG, 
VLDL - TG and VLDL cholesterol level 
  63442G KIM et al. 2009 Lower WC 
rs1044471    KIM et al. 2009 Lower WC 
  35361A>G  RUCHAT et al. 2008 No associations with insulin sensitivity 
  1352G>A  RUCHAT et al. 2008 No associations with insulin sensitivity 
 
870C/A, 
Ile290Ile 
 
BROEDL et al. 2006 
 
 
Higher plasma adiponectin, lower fasting TG, 
VLDL - TG and VLDL cholesterol level 
rs9805042 
 
 
963C/T 
 
 
BROEDL et al. 2006 
 
 
Higher plasma adiponectin, lower fasting TG, 
VLDL - TG and VLDL cholesterol level 
rs10920533 
    FERGUSON et al. 2010 
Plasma saturated fatty acids 
 
rs767870   
HELVATSIOSIS et al. 
2010 
AdipoR2 levels 
 
    KOTRONEN et al. 2009 
Fat accumulation in liver 
 
CDH13     
rs7195409   LING et al. 2009 Adiponectin levels 
Table 9: Overview of all ADIPOR1, ADIPOR2 and CDH13 polymorphisms and their 
associations 
 
Additional results have been reported by SCUTERI et al. (2007), who have 
carried out a GWAS focusing on associations between genetic variants in the 
FTO gene and obesity related traits. Their study population existed of 6148 
subjects from an isolated population from Sardinia, which had 362.129 SNPs 
checked for association with BMI, hip circumference and weight. An 
additional 74 candidate genes have been analyzed as they might also 
influence obesity and related traits. Within that study ADIPOR1 and 
ADIPOR2 have shown a moderate association with BMI, hip circumference 
and weight (ADIPOR1: p-values = 0.013, 0.027 and 0.016, ADIPOR2: p-
values= 0.018, 0.019 and 0.013). 
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5.4.3. ADIPOR1, ADIPOR2 and CDH13 - Discussion 
 
Generally it can be said that, like for the previously reported polymorphisms 
on other genes, no real statement can be made. Only one SNP, rs16928751, 
has been mentioned twice and even for that one opposing results have been 
reported. 
 
For ADIPOR1, ADIPOR2, CDH13 further research is definitely needed if 
results are to be confirmed. It has been very surprising that GWAS have 
reported significant results for CDH13 only, as this receptor is new and not 
much effect has been thought to be coming from it. But it remains to be 
elucidated how this receptor transduces signals when adiponectin binds to it. 
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6. Conclusion 
 
Although the attention to MetS has risen constantly over the years and a lot 
of research has been done to understand this cluster of diseases it is still an 
equation with various unknown parts and therefore a subject of frequent 
research. 
 
As mentioned in the first chapter of the thesis there is no standardized 
definition available for MetS. But this would be crucial for enabeling the 
comparison of study data and for lowering the degree of disparity in 
diagnosing the cluster of diseases. But not only MetS as a whole has been 
shown to be problematic. Not fully elucidated pathogenesis of each of the 
components, undefined cut-off points, the exclusion of inflammation in the 
general definition as well as the use of imperfect surrogates only emphasize 
that there is still a lot to be investigated and learned about MetS.  
 
The aim of this thesis was to show the role of leptin and adiponectin as well 
as their receptors in the development of MetS. Especially the SNPs of their 
encoding genes and their associations with MetS features have been in the 
focus.  And this has not been unproblematic. To the already existing 
problems of MetS a new field of research has been added, therefore all 
results have to be interpreted with care. When it is not sure that the person is 
diseased or not, it is not possible to tell if the present associations are true or 
falsely positive. Whereas the literature research revealed almost no results 
for LEP polymorphisms, LEPR, ADIPOQ and adiponectin receptor SNPs 
have been more promising. But neither trailblazing nor even meaningful 
results were present pointing out that there are still gaps in the knowledge 
that have to be filled before more can be said.  
 
If GWAS and the research of polymorphisms should be kept up depends on 
the point of view on the topic. These kinds of studies are still in the fledging 
stages and there might be positive results in the future. However, as always 
in science, those are not guaranteed. If the main goal is to attach functions to 
the findings and fill in the gaps of knowledge then GWAS should definitely be 
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kept up. If it is only for assessing the possible risk for an individual to get the 
disease, then, at the moment, GWAS do not seem promising. In the case of 
MetS, it can generally be said that genetic screenings have no informative 
value at the moment. The only way of preventing the development of the 
disease cluster is the integration of better health habits in every day life. 
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7. Summary 
 
The attention to metabolic syndrome has risen constantly over the years as 
the disease is leading to disability and premature death in an increasing 
number of affected people. Next to environmental factors, genes and gene 
variations have been considered to play a role in causation. Leptin and 
adiponectin, two adipocytokines, as well as their receptors, have been the 
focus of this thesis as they (together with their polymorphisms) have been 
linked to metabolic syndrome features. Genome-wide association studies 
have been a novel approach to find these genetic variations and until now 
they have reported numerous outcomes. The literature research at hand 
revealed various results pointing out that current knowledge is not enough to 
explain to which extent the adipocytokines play a role in the development of 
MetS. Genetic screenings for risk assessement cannot be recommended at 
the moment. The incorporation of better health habits to prevent the 
metabolic syndrome and/or any of its features should be in the focus instead. 
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8. Zusammenfassung 
 
Das Metabolische Syndrom hat über die Jahre immer mehr die 
Aufmerksamkeit auf sich gezogen, da es zu Invalidität und vorzeitigem Tod 
bei einer steigenden Anzahl an Betroffenen führt. Neben der Umwelt sind 
immer wieder die Gene und deren Veränderungen  worden, die Krankheit zu 
verursachen. Leptin und Adiponectin, zwei Adipozytokine, sowie ihre 
Rezeptoren sind das Hauptaugenmerk dieser Diplomarbeit, da sie und ihre 
genetischen Polymorphismen mit dem Metabolischen Syndrom in 
Verbindung gebracht worden sind. Genomweite Assoziationsstudien stellen 
eine neue Vorgehensweise dar, diese genetischen Veränderungen zu finden. 
Die Ergebnisse der vorliegenden Literaturrecherche sind sehr inkonsistent 
ausgefallen und weisen darauf hin, dass nach dem derzeitigen Wissensstand 
nicht gesagt werden kann in welchem Ausmass die Adipozytokine in der 
Entstehung vom MetS eine Rolle spielen. Im Moment können keine 
genetischen Screenings zur Risikobewertung empfohlen werden. Das 
Einfügen von gesunden Verhaltensweisen in das Alltagsleben und nicht ein 
genetisches Screening sollten im Mittelpunkt der Prävention vom 
Metabolischen Syndrom sein. 
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